###begin article-title 0
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
###end article-title 0
###begin p 1
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Background</italic>
###xml 209 216 209 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Methods</italic>
###xml 609 616 609 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Results</italic>
###xml 680 681 680 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 800 801 800 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 843 844 843 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 877 878 877 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1283 1284 1283 1284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1349 1350 1349 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1387 1398 1387 1398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Conclusions</italic>
Background Expression of aromatase by malignant breast epithelial cells and/or the surrounding stroma implies local estrogen production that could influence the outcome of endocrine therapy for breast cancer. Methods A validated immunohistochemical assay for aromatase was applied to samples from the P024 neoadjuvant endocrine therapy trial that compared tamoxifen and letrozole. The presence of aromatase expression by tumor or stromal cells was correlated with tumor response, treatment induced changes in proliferation index (Ki67), relapse-free survival (RFS) and breast cancer-specific survival (BCSS). Results Tumor and stromal aromatase expression were highly correlated (P = 0.0001). Tumor cell aromatase, as a semi-continuous score, also correlated with smaller tumor size at presentation (P = 0.01) higher baseline ER Allred score (P = 0.006) and lower Ki67 levels (P = 0.003). There was no significant relationship with clinical response or treatment-induced changes in Ki67. However, in a Cox multivariable model that incorporated a post-treatment tumor profile (pathological T stage, N stage, Ki67 and ER status of the surgical specimen), the presence of tumor aromatase expression at baseline sample remained a favorable independent prognostic biomarker for both RFS (P = 0.01, HR 2.3, 95% CI 1.2-4.6 for absent expression) and BCSS (P = 0.008, HR 3.76, 95% CI 1.4-10.0). Conclusions Autocrine estrogen synthesis may be most characteristic of smaller, more indolent and ER-rich breast cancers with lower baseline growth rates. However, response to endocrine treatment may not depend on whether the estrogenic stimulus has a local versus systemic source.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 578 579 578 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 840 841 840 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 842 843 842 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 972 973 972 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 975 976 975 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1378 1379 1378 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1425 1427 1425 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 830 838 <span type="species:ncbi:9606">patients</span>
After the menopause, estrogen continues to be synthesized through peripheral conversion of androgenic precursors to estrone and estradiol by the CYP P450 enzyme aromatase (CYP19). Since this enzyme is widely expressed, sources of estrogen for breast cancers can therefore be through the circulation (endocrine), from within the breast stroma (paracrine) or through synthesis by the tumor cell (autocrine) [1, 2]. Intra-tumoral estrogen production has been directly demonstrated by measuring the conversion of radio-labeled androgen to estrogen in breast cancer biopsy material [1-3]. However correlations between biochemical measurements of intra-tumoral estrogen synthesis and clinical outcomes have not been firmly established, largely because in vivo assays of aromatase activity are difficult to execute in a large numbers of patients [4-6]. As alternative approaches, aromatase immunohistochemistry (IHC) and measurements of aromatase mRNA levels have been explored [7, 8]. However, most investigators have not validated their IHC assays against the "gold standard" of a biochemical assay for intra-tumoral aromatase activity. Our group has recently developed and characterized a monoclonal antibody against aromatase. The antibody has been utilized in IHC studies which demonstrated positive correlations between aromatase IHC scores and intra-tumoral aromatase activity [9] and aromatase mRNA expression measurements [10] in breast cancer specimens.
###end p 4
###begin p 5
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 121 129 <span type="species:ncbi:9606">patients</span>
###xml 558 566 <span type="species:ncbi:9606">patients</span>
In this investigation we applied the aromatase IHC assay to formalin-fixed paraffin-embedded biopsy samples accrued from patients enrolled onto the P024 neoadjuvant endocrine therapy study, a Phase III double blind randomized trial that compared four months neoadjuvant tamoxifen with an equivalent period of letrozole treatment [11-13]. The design of this study provided a valuable opportunity to evaluate simultaneously the relationship between tumor aromatase expression and response to neoadjuvant endocrine therapy as well as the long-term outcomes for patients receiving adjuvant tamoxifen treatment.
###end p 5
###begin title 6
Methods
###end title 6
###begin title 7
Study population and tumor bank
###end title 7
###begin p 8
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 95 100 <span type="species:ncbi:9606">women</span>
The P024 protocol compared four months neoadjuvant letrozole with tamoxifen in post-menopausal women with clinical stage II and III hormone receptor positive (classified as at least 10% nuclear staining for ER and/or PgR) breast cancers that were ineligible for breast conservative surgery [11]. The tumor bank characteristics, ER and Ki67 measurements have been described previously [12, 13]. Tumor grade, tumor histological subtype, pathological staging information and long-term outcomes were collated from case report forms. The long-term outcomes and the development of the preoperative endocrine prognostic index (PEPI) based on pathological stage, and the ER status and Ki67 expression level of the surgical specimen has also been published [14].
###end p 8
###begin title 9
Aromatase immunohistochemistry
###end title 9
###begin p 10
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 77 82 <span type="species:ncbi:9606">human</span>
The aromatase monoclonal antibody #677 was raised against native recombinant human aromatase protein. Details of its characterization and utilization for IHC have been previously reported [9]. Tissue sections were immunostained by a biotin-streptavidin method using a Histofine kit (Nichirei Co. Ltd., Tokyo, Japan). The antigen-antibody complex was visualized with 3.3'-diaminobenzidine solution (DAB) and counterstained with hematoxylin. Evaluation of aromatase IHC was performed by assessing the approximate percentage of cells staining (proportion score) and classifying the level into four groups: 0 = <1%, 1 = 1-25%, 2 = 26-50%, and 3 = >50% immuno-positive cells. The relative intensity of aromatase immune-positive cells was classified as follows: 0 = no immunoreactivity, 1 = weak, 2 = moderate and 3 = intense immunoreactivity. When aromatase immunoreactivity was evaluated as a semi-continuous variable, a total score was applied that was composed of the proportion score + relative immuno-intensity score (SIP score). For contingency table analysis, aromatase staining was classified as any staining present versus absent staining. Immunohistochemical staining patterns of normal ducts, stromal cells, adipose cells and carcinoma cells were evaluated separately.
###end p 10
###begin title 11
Statistics
###end title 11
###begin p 12
###xml 4 5 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 38 40 38 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 1847 1849 1845 1847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1927 1929 1925 1927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
All P values reported were two sided; P </= 0.05 were considered to be statistically significant. There was no adjustment for multiple testing. The median and inter-quartile range of the aromatase SIP score was calculated to show the distribution of scores. Kendall's rank correlation coefficients were used to assess relationship between aromatase SIP values and Ki67, ER, and tumor size since aromatase SIP values were ordinal variables and not normal distributed. Fisher's exact and Chi squared tests were used to define associations between aromatase expression status and clinical and cell cycle responses. The non-parametric Mann-Whitney test was applied to compare differences in Ki67 changes between aromatase expression positive and aromatase expression negative tumors. The 95% confidence interval of the geometric Ki67 mean was calculated to show the size of effects in pair-wise comparisons. Relapse-free survival (RFS) was defined as the interval between randomization and the earliest subsequent breast cancer event (all local or systemic recurrences, there were no new breast primaries recorded in this data set). Breast cancer-specific survival (BCSS) was defined as the interval between randomization and the date of death after breast cancer relapse. For univariable analysis, survival curves were estimated by the Kaplan-Meier product-limit method, with a two-sided log-rank to assess statistically significant differences. We subsequently applied a multivariate Cox proportional hazards regression model to evaluate the independent prognostic relevance of aromatase expression within the context of other independently prognostic variables that were obtained upon analysis of the surgical specimen obtained after completion of neoadjuvant endocrine therapy: i.e. pathological tumor size, lymph node status, ER and Ki67 levels [14]. The REMARK analysis for the multivariable analysis has also been reported [14]. All statistical analyses were performed using SAS 9.1.2 (SAS Institute Inc., Cary NC USA).
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
Aromatase expression and correlation with baseline pathological and clinical variables
###end title 14
###begin p 15
###xml 948 949 948 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 965 966 965 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1078 1079 1078 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1094 1095 1094 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1315 1316 1315 1316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1330 1331 1330 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1889 1890 1889 1890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1892 1898 1892 1898 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 2092 2093 2092 2093 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2155 2156 2155 2156 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2220 2221 2220 2221 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1898 2388 1898 2388 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="16">Correlations between the site of aromatase expression, ER and Ki67 as semi-continuous variables. Box plots comparing the distributions of aromatase SIP scores in stromal cells and cancer cells (<bold>a</bold>), aromatase SIP scores in cancer cells and ER Allred scores (<bold>b</bold>) and Ki67 percentage and aromatase SIP scores in cancer cells (<bold>c</bold>) at baseline. The large boxes stretch from the 25th to 75th percentile, the lines crossing the boxes are medians, the dots are means and the small boxes are outliers.</p>
###xml 1898 2388 1898 2388 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="16">Correlations between the site of aromatase expression, ER and Ki67 as semi-continuous variables. Box plots comparing the distributions of aromatase SIP scores in stromal cells and cancer cells (<bold>a</bold>), aromatase SIP scores in cancer cells and ER Allred scores (<bold>b</bold>) and Ki67 percentage and aromatase SIP scores in cancer cells (<bold>c</bold>) at baseline. The large boxes stretch from the 25th to 75th percentile, the lines crossing the boxes are medians, the dots are means and the small boxes are outliers.</p></caption>
###xml 2388 2388 2388 2388 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10549_2008_161_Fig1_HTML" id="MO1"/>
###xml 1892 2388 1892 2388 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="16">Correlations between the site of aromatase expression, ER and Ki67 as semi-continuous variables. Box plots comparing the distributions of aromatase SIP scores in stromal cells and cancer cells (<bold>a</bold>), aromatase SIP scores in cancer cells and ER Allred scores (<bold>b</bold>) and Ki67 percentage and aromatase SIP scores in cancer cells (<bold>c</bold>) at baseline. The large boxes stretch from the 25th to 75th percentile, the lines crossing the boxes are medians, the dots are means and the small boxes are outliers.</p></caption><graphic position="anchor" xlink:href="10549_2008_161_Fig1_HTML" id="MO1"/></fig>
###xml 2388 2395 2388 2395 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 2395 2493 2395 2493 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17">Patients and tumors characteristics by location of aromatase protein expression status at baseline</p>
###xml 2395 2493 2395 2493 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="17">Patients and tumors characteristics by location of aromatase protein expression status at baseline</p></caption>
###xml 2493 2508 2493 2508 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Characteristics</th>
###xml 2538 2539 2538 2539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2544 2545 2544 2545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2508 2545 2508 2545 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Aromatase protein expression [<italic>n</italic> (%)]<sup>b</sup></th>
###xml 2493 2545 2493 2545 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="3">Characteristics</th><th align="left" colspan="4">Aromatase protein expression [<italic>n</italic> (%)]<sup>b</sup></th></tr>
###xml 2545 2571 2545 2571 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Tumor epithelial aromatase</th>
###xml 2571 2588 2571 2588 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Stromal aromatase</th>
###xml 2545 2588 2545 2588 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="2">Tumor epithelial aromatase</th><th align="left" colspan="2">Stromal aromatase</th></tr>
###xml 2588 2596 2588 2596 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</th>
###xml 2596 2604 2596 2604 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</th>
###xml 2604 2612 2604 2612 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</th>
###xml 2612 2620 2612 2620 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</th>
###xml 2588 2620 2588 2620 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Negative</th><th align="left">Positive</th><th align="left">Negative</th><th align="left">Positive</th></tr>
###xml 2493 2620 2493 2620 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="3">Characteristics</th><th align="left" colspan="4">Aromatase protein expression [<italic>n</italic> (%)]<sup>b</sup></th></tr><tr><th align="left" colspan="2">Tumor epithelial aromatase</th><th align="left" colspan="2">Stromal aromatase</th></tr><tr><th align="left">Negative</th><th align="left">Positive</th><th align="left">Negative</th><th align="left">Positive</th></tr></thead>
###xml 2620 2629 2620 2629 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Treatment</td>
###xml 2620 2629 2620 2629 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Treatment</td></tr>
###xml 2629 2642 2629 2642 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Tamoxifen</td>
###xml 2642 2650 2642 2650 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">24 (53%)</td>
###xml 2650 2658 2650 2658 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">72 (49%)</td>
###xml 2658 2665 2658 2665 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">29 (54)</td>
###xml 2665 2672 2665 2672 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">63 (48)</td>
###xml 2629 2672 2629 2672 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Tamoxifen</td><td char="." align="left">24 (53%)</td><td char="." align="left">72 (49%)</td><td char="." align="left">29 (54)</td><td char="." align="left">63 (48)</td></tr>
###xml 2672 2685 2672 2685 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Letrozole</td>
###xml 2685 2693 2685 2693 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">21 (47%)</td>
###xml 2693 2701 2693 2701 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">75 (51%)</td>
###xml 2701 2708 2701 2708 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">25 (46)</td>
###xml 2708 2715 2708 2715 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">69 (52)</td>
###xml 2672 2715 2672 2715 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Letrozole</td><td char="." align="left">21 (47%)</td><td char="." align="left">75 (51%)</td><td char="." align="left">25 (46)</td><td char="." align="left">69 (52)</td></tr>
###xml 2719 2720 2719 2720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2715 2726 2715 2726 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 2726 2732 2726 2732 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.6102</td>
###xml 2732 2738 2732 2738 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.4605</td>
###xml 2715 2738 2715 2738 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.6102</td><td char="." align="left" colspan="2">0.4605</td></tr>
###xml 2738 2748 2738 2748 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age (year)</td>
###xml 2748 2752 2748 2752 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">66.8</td>
###xml 2752 2756 2752 2756 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">67.6</td>
###xml 2756 2760 2756 2760 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">67.6</td>
###xml 2760 2762 2760 2762 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">67</td>
###xml 2738 2762 2738 2762 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Age (year)</td><td char="." align="left">66.8</td><td char="." align="left">67.6</td><td char="." align="left">67.6</td><td char="." align="left">67</td></tr>
###xml 2766 2767 2766 2767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2773 2774 2773 2774 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 2762 2774 2762 2774 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>c</sup></td>
###xml 2774 2780 2774 2780 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.6214</td>
###xml 2780 2786 2780 2786 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.6969</td>
###xml 2762 2786 2762 2786 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>c</sup></td><td char="." align="left" colspan="2">0.6214</td><td char="." align="left" colspan="2">0.6969</td></tr>
###xml 2786 2810 2786 2810 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Clinical tumor size (cm)</td>
###xml 2810 2813 2810 2813 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">5.7</td>
###xml 2813 2816 2813 2816 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">4.8</td>
###xml 2816 2819 2816 2819 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">5.5</td>
###xml 2819 2822 2819 2822 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">4.7</td>
###xml 2786 2822 2786 2822 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Clinical tumor size (cm)</td><td char="." align="left">5.7</td><td char="." align="left">4.8</td><td char="." align="left">5.5</td><td char="." align="left">4.7</td></tr>
###xml 2826 2827 2826 2827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2833 2834 2833 2834 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 2822 2834 2822 2834 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>c</sup></td>
###xml 2834 2840 2834 2840 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.0144</td>
###xml 2840 2846 2840 2846 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.0398</td>
###xml 2822 2846 2822 2846 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>c</sup></td><td char="." align="left" colspan="2">0.0144</td><td char="." align="left" colspan="2">0.0398</td></tr>
###xml 2846 2865 2846 2865 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Pre treatment grade</td>
###xml 2846 2865 2846 2865 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Pre treatment grade</td></tr>
###xml 2865 2870 2865 2870 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;I</td>
###xml 2870 2877 2870 2877 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">4 (10%)</td>
###xml 2877 2885 2877 2885 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">16 (13%)</td>
###xml 2885 2891 2885 2891 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">4 (8%)</td>
###xml 2891 2899 2891 2899 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">16 (15%)</td>
###xml 2865 2899 2865 2899 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;I</td><td char="." align="left">4 (10%)</td><td char="." align="left">16 (13%)</td><td char="." align="left">4 (8%)</td><td char="." align="left">16 (15%)</td></tr>
###xml 2899 2909 2899 2909 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;II/III</td>
###xml 2909 2917 2909 2917 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">38 (90%)</td>
###xml 2917 2926 2917 2926 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">103 (87%)</td>
###xml 2926 2934 2926 2934 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">47 (92%)</td>
###xml 2934 2942 2934 2942 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">90 (85%)</td>
###xml 2899 2942 2899 2942 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;II/III</td><td char="." align="left">38 (90%)</td><td char="." align="left">103 (87%)</td><td char="." align="left">47 (92%)</td><td char="." align="left">90 (85%)</td></tr>
###xml 2946 2947 2946 2947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2942 2953 2942 2953 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 2953 2959 2953 2959 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.5971</td>
###xml 2959 2965 2959 2965 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.3064</td>
###xml 2942 2965 2942 2965 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.5971</td><td char="." align="left" colspan="2">0.3064</td></tr>
###xml 2965 2988 2965 2988 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Pathological tumor size</td>
###xml 2965 2988 2965 2988 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Pathological tumor size</td></tr>
###xml 2988 3000 2988 2998 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;&#8804;20&#160;mm</td>
###xml 3000 3008 2998 3006 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">11 (27%)</td>
###xml 3008 3016 3006 3014 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">44 (32%)</td>
###xml 3016 3024 3014 3022 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">11 (27%)</td>
###xml 3024 3032 3022 3030 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">44 (32%)</td>
###xml 2988 3032 2988 3030 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;&#8804;20&#160;mm</td><td char="." align="left">11 (27%)</td><td char="." align="left">44 (32%)</td><td char="." align="left">11 (27%)</td><td char="." align="left">44 (32%)</td></tr>
###xml 3032 3042 3030 3040 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;&gt;20&#160;mm</td>
###xml 3042 3050 3040 3048 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">30 (73%)</td>
###xml 3050 3058 3048 3056 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">95 (68%)</td>
###xml 3058 3066 3056 3064 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">30 (73%)</td>
###xml 3066 3074 3064 3072 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">95 (68%)</td>
###xml 3032 3074 3030 3072 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;&gt;20&#160;mm</td><td char="." align="left">30 (73%)</td><td char="." align="left">95 (68%)</td><td char="." align="left">30 (73%)</td><td char="." align="left">95 (68%)</td></tr>
###xml 3078 3079 3076 3077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 3074 3085 3072 3083 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 3085 3091 3083 3089 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.5567</td>
###xml 3091 3097 3089 3095 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.5567</td>
###xml 3074 3097 3072 3095 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.5567</td><td char="." align="left" colspan="2">0.5567</td></tr>
###xml 3097 3121 3095 3119 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Pathological node status</td>
###xml 3097 3121 3095 3119 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Pathological node status</td></tr>
###xml 3121 3133 3119 3131 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Negative</td>
###xml 3133 3141 3131 3139 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">16 (41%)</td>
###xml 3141 3149 3139 3147 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">55 (43%)</td>
###xml 3149 3157 3147 3155 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">21 (47%)</td>
###xml 3157 3165 3155 3163 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">50 (43%)</td>
###xml 3121 3165 3119 3163 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">16 (41%)</td><td char="." align="left">55 (43%)</td><td char="." align="left">21 (47%)</td><td char="." align="left">50 (43%)</td></tr>
###xml 3165 3177 3163 3175 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Positive</td>
###xml 3177 3185 3175 3183 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">23 (59%)</td>
###xml 3185 3193 3183 3191 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">72 (57%)</td>
###xml 3193 3201 3191 3199 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">24 (53%)</td>
###xml 3201 3209 3199 3207 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">65 (57%)</td>
###xml 3165 3209 3163 3207 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">23 (59%)</td><td char="." align="left">72 (57%)</td><td char="." align="left">24 (53%)</td><td char="." align="left">65 (57%)</td></tr>
###xml 3213 3214 3211 3212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 3209 3220 3207 3218 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 3220 3226 3218 3224 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.8017</td>
###xml 3226 3232 3224 3230 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.7160</td>
###xml 3209 3232 3207 3230 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.8017</td><td char="." align="left" colspan="2">0.7160</td></tr>
###xml 3243 3244 3241 3242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 3232 3244 3230 3242 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">HER2 status<sup>a</sup></td>
###xml 3232 3244 3230 3242 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">HER2 status<sup>a</sup></td></tr>
###xml 3244 3256 3242 3254 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Negative</td>
###xml 3256 3264 3254 3262 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">40 (91%)</td>
###xml 3264 3273 3262 3271 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">140 (95%)</td>
###xml 3273 3281 3271 3279 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">50 (93%)</td>
###xml 3281 3290 3279 3288 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">125 (95%)</td>
###xml 3244 3290 3242 3288 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">40 (91%)</td><td char="." align="left">140 (95%)</td><td char="." align="left">50 (93%)</td><td char="." align="left">125 (95%)</td></tr>
###xml 3290 3302 3288 3300 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Positive</td>
###xml 3302 3308 3300 3306 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">4 (9%)</td>
###xml 3308 3314 3306 3312 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">7 (5%)</td>
###xml 3314 3320 3312 3318 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">4 (7%)</td>
###xml 3320 3326 3318 3324 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">6 (5%)</td>
###xml 3290 3326 3288 3324 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">4 (9%)</td><td char="." align="left">7 (5%)</td><td char="." align="left">4 (7%)</td><td char="." align="left">6 (5%)</td></tr>
###xml 3330 3331 3328 3329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 3326 3337 3324 3335 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 3337 3343 3335 3341 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.2806</td>
###xml 3343 3349 3341 3347 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.4810</td>
###xml 3326 3349 3324 3347 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.2806</td><td char="." align="left" colspan="2">0.4810</td></tr>
###xml 3358 3359 3356 3357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 3349 3359 3347 3357 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">ER status<sup>c</sup></td>
###xml 3349 3359 3347 3357 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">ER status<sup>c</sup></td></tr>
###xml 3359 3371 3357 3369 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Negative</td>
###xml 3371 3379 3369 3377 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">11 (20%)</td>
###xml 3379 3386 3377 3384 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">12 (8%)</td>
###xml 3386 3394 3384 3392 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">14 (20%)</td>
###xml 3394 3400 3392 3398 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">9 (6%)</td>
###xml 3359 3400 3357 3398 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">11 (20%)</td><td char="." align="left">12 (8%)</td><td char="." align="left">14 (20%)</td><td char="." align="left">9 (6%)</td></tr>
###xml 3400 3412 3398 3410 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Positive</td>
###xml 3412 3420 3410 3418 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">44 (80%)</td>
###xml 3420 3429 3418 3427 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">148 (93%)</td>
###xml 3429 3437 3427 3435 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">55 (80%)</td>
###xml 3437 3446 3435 3444 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">131 (94%)</td>
###xml 3400 3446 3398 3444 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">44 (80%)</td><td char="." align="left">148 (93%)</td><td char="." align="left">55 (80%)</td><td char="." align="left">131 (94%)</td></tr>
###xml 3450 3451 3448 3449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 3446 3457 3444 3455 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 3457 3463 3455 3461 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.0098</td>
###xml 3463 3469 3461 3467 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.0027</td>
###xml 3446 3469 3444 3467 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.0098</td><td char="." align="left" colspan="2">0.0027</td></tr>
###xml 3479 3480 3477 3478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 3469 3480 3467 3478 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">PgR status<sup>c</sup></td>
###xml 3469 3480 3467 3478 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">PgR status<sup>c</sup></td></tr>
###xml 3480 3492 3478 3490 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Negative</td>
###xml 3492 3500 3490 3498 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">16 (36%)</td>
###xml 3500 3508 3498 3506 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">48 (33%)</td>
###xml 3508 3516 3506 3514 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">20 (37%)</td>
###xml 3516 3524 3514 3522 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">43 (33%)</td>
###xml 3480 3524 3478 3522 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">16 (36%)</td><td char="." align="left">48 (33%)</td><td char="." align="left">20 (37%)</td><td char="." align="left">43 (33%)</td></tr>
###xml 3524 3536 3522 3534 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Positive</td>
###xml 3536 3544 3534 3542 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">28 (64%)</td>
###xml 3544 3552 3542 3550 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">98 (67%)</td>
###xml 3552 3560 3550 3558 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">34 (63%)</td>
###xml 3560 3568 3558 3566 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">87 (67%)</td>
###xml 3524 3568 3522 3566 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">28 (64%)</td><td char="." align="left">98 (67%)</td><td char="." align="left">34 (63%)</td><td char="." align="left">87 (67%)</td></tr>
###xml 3572 3573 3570 3571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 3568 3579 3566 3577 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 3579 3585 3577 3583 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.6688</td>
###xml 3585 3591 3583 3589 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.6072</td>
###xml 3568 3591 3566 3589 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.6688</td><td char="." align="left" colspan="2">0.6072</td></tr>
###xml 2620 3591 2620 3589 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" colspan="5">Treatment</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Tamoxifen</td><td char="." align="left">24 (53%)</td><td char="." align="left">72 (49%)</td><td char="." align="left">29 (54)</td><td char="." align="left">63 (48)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Letrozole</td><td char="." align="left">21 (47%)</td><td char="." align="left">75 (51%)</td><td char="." align="left">25 (46)</td><td char="." align="left">69 (52)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.6102</td><td char="." align="left" colspan="2">0.4605</td></tr><tr><td align="left">Age (year)</td><td char="." align="left">66.8</td><td char="." align="left">67.6</td><td char="." align="left">67.6</td><td char="." align="left">67</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>c</sup></td><td char="." align="left" colspan="2">0.6214</td><td char="." align="left" colspan="2">0.6969</td></tr><tr><td align="left">Clinical tumor size (cm)</td><td char="." align="left">5.7</td><td char="." align="left">4.8</td><td char="." align="left">5.5</td><td char="." align="left">4.7</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>c</sup></td><td char="." align="left" colspan="2">0.0144</td><td char="." align="left" colspan="2">0.0398</td></tr><tr><td align="left" colspan="5">Pre treatment grade</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;I</td><td char="." align="left">4 (10%)</td><td char="." align="left">16 (13%)</td><td char="." align="left">4 (8%)</td><td char="." align="left">16 (15%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;II/III</td><td char="." align="left">38 (90%)</td><td char="." align="left">103 (87%)</td><td char="." align="left">47 (92%)</td><td char="." align="left">90 (85%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.5971</td><td char="." align="left" colspan="2">0.3064</td></tr><tr><td align="left" colspan="5">Pathological tumor size</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;&#8804;20&#160;mm</td><td char="." align="left">11 (27%)</td><td char="." align="left">44 (32%)</td><td char="." align="left">11 (27%)</td><td char="." align="left">44 (32%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;&gt;20&#160;mm</td><td char="." align="left">30 (73%)</td><td char="." align="left">95 (68%)</td><td char="." align="left">30 (73%)</td><td char="." align="left">95 (68%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.5567</td><td char="." align="left" colspan="2">0.5567</td></tr><tr><td align="left" colspan="5">Pathological node status</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">16 (41%)</td><td char="." align="left">55 (43%)</td><td char="." align="left">21 (47%)</td><td char="." align="left">50 (43%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">23 (59%)</td><td char="." align="left">72 (57%)</td><td char="." align="left">24 (53%)</td><td char="." align="left">65 (57%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.8017</td><td char="." align="left" colspan="2">0.7160</td></tr><tr><td align="left" colspan="5">HER2 status<sup>a</sup></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">40 (91%)</td><td char="." align="left">140 (95%)</td><td char="." align="left">50 (93%)</td><td char="." align="left">125 (95%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">4 (9%)</td><td char="." align="left">7 (5%)</td><td char="." align="left">4 (7%)</td><td char="." align="left">6 (5%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.2806</td><td char="." align="left" colspan="2">0.4810</td></tr><tr><td align="left" colspan="5">ER status<sup>c</sup></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">11 (20%)</td><td char="." align="left">12 (8%)</td><td char="." align="left">14 (20%)</td><td char="." align="left">9 (6%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">44 (80%)</td><td char="." align="left">148 (93%)</td><td char="." align="left">55 (80%)</td><td char="." align="left">131 (94%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.0098</td><td char="." align="left" colspan="2">0.0027</td></tr><tr><td align="left" colspan="5">PgR status<sup>c</sup></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">16 (36%)</td><td char="." align="left">48 (33%)</td><td char="." align="left">20 (37%)</td><td char="." align="left">43 (33%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">28 (64%)</td><td char="." align="left">98 (67%)</td><td char="." align="left">34 (63%)</td><td char="." align="left">87 (67%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.6688</td><td char="." align="left" colspan="2">0.6072</td></tr></tbody>
###xml 2493 3591 2493 3589 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Characteristics</th><th align="left" colspan="4">Aromatase protein expression [<italic>n</italic> (%)]<sup>b</sup></th></tr><tr><th align="left" colspan="2">Tumor epithelial aromatase</th><th align="left" colspan="2">Stromal aromatase</th></tr><tr><th align="left">Negative</th><th align="left">Positive</th><th align="left">Negative</th><th align="left">Positive</th></tr></thead><tbody><tr><td align="left" colspan="5">Treatment</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Tamoxifen</td><td char="." align="left">24 (53%)</td><td char="." align="left">72 (49%)</td><td char="." align="left">29 (54)</td><td char="." align="left">63 (48)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Letrozole</td><td char="." align="left">21 (47%)</td><td char="." align="left">75 (51%)</td><td char="." align="left">25 (46)</td><td char="." align="left">69 (52)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.6102</td><td char="." align="left" colspan="2">0.4605</td></tr><tr><td align="left">Age (year)</td><td char="." align="left">66.8</td><td char="." align="left">67.6</td><td char="." align="left">67.6</td><td char="." align="left">67</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>c</sup></td><td char="." align="left" colspan="2">0.6214</td><td char="." align="left" colspan="2">0.6969</td></tr><tr><td align="left">Clinical tumor size (cm)</td><td char="." align="left">5.7</td><td char="." align="left">4.8</td><td char="." align="left">5.5</td><td char="." align="left">4.7</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>c</sup></td><td char="." align="left" colspan="2">0.0144</td><td char="." align="left" colspan="2">0.0398</td></tr><tr><td align="left" colspan="5">Pre treatment grade</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;I</td><td char="." align="left">4 (10%)</td><td char="." align="left">16 (13%)</td><td char="." align="left">4 (8%)</td><td char="." align="left">16 (15%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;II/III</td><td char="." align="left">38 (90%)</td><td char="." align="left">103 (87%)</td><td char="." align="left">47 (92%)</td><td char="." align="left">90 (85%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.5971</td><td char="." align="left" colspan="2">0.3064</td></tr><tr><td align="left" colspan="5">Pathological tumor size</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;&#8804;20&#160;mm</td><td char="." align="left">11 (27%)</td><td char="." align="left">44 (32%)</td><td char="." align="left">11 (27%)</td><td char="." align="left">44 (32%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;&gt;20&#160;mm</td><td char="." align="left">30 (73%)</td><td char="." align="left">95 (68%)</td><td char="." align="left">30 (73%)</td><td char="." align="left">95 (68%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.5567</td><td char="." align="left" colspan="2">0.5567</td></tr><tr><td align="left" colspan="5">Pathological node status</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">16 (41%)</td><td char="." align="left">55 (43%)</td><td char="." align="left">21 (47%)</td><td char="." align="left">50 (43%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">23 (59%)</td><td char="." align="left">72 (57%)</td><td char="." align="left">24 (53%)</td><td char="." align="left">65 (57%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.8017</td><td char="." align="left" colspan="2">0.7160</td></tr><tr><td align="left" colspan="5">HER2 status<sup>a</sup></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">40 (91%)</td><td char="." align="left">140 (95%)</td><td char="." align="left">50 (93%)</td><td char="." align="left">125 (95%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">4 (9%)</td><td char="." align="left">7 (5%)</td><td char="." align="left">4 (7%)</td><td char="." align="left">6 (5%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.2806</td><td char="." align="left" colspan="2">0.4810</td></tr><tr><td align="left" colspan="5">ER status<sup>c</sup></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">11 (20%)</td><td char="." align="left">12 (8%)</td><td char="." align="left">14 (20%)</td><td char="." align="left">9 (6%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">44 (80%)</td><td char="." align="left">148 (93%)</td><td char="." align="left">55 (80%)</td><td char="." align="left">131 (94%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.0098</td><td char="." align="left" colspan="2">0.0027</td></tr><tr><td align="left" colspan="5">PgR status<sup>c</sup></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">16 (36%)</td><td char="." align="left">48 (33%)</td><td char="." align="left">20 (37%)</td><td char="." align="left">43 (33%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">28 (64%)</td><td char="." align="left">98 (67%)</td><td char="." align="left">34 (63%)</td><td char="." align="left">87 (67%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.6688</td><td char="." align="left" colspan="2">0.6072</td></tr></tbody></table>
###xml 3591 3592 3589 3590 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 3717 3719 3715 3717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 3591 3720 3589 3718 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18"><sup>a</sup>HER2 IHC with fluorescence in situ hybridization confirmation and IHC for ER and PgR were performed as previously described [<xref ref-type="bibr" rid="CR12">12</xref>]</p>
###xml 3720 3721 3718 3719 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 3720 3811 3718 3809 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="19"><sup>b</sup>Aromatase protein expression considered positive if any aromatase IHC staining was present</p>
###xml 3811 3812 3809 3810 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 3858 3859 3856 3857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 3954 3955 3952 3953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 3955 3956 3953 3954 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 3811 4037 3809 4035 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="20"><sup>c</sup>For age and clinical tumor size the student&#8217;s <italic>t</italic> test was used to compare the aromatase positive and negative groups. For binary variables the <italic>X</italic><sup>2</sup> test was applied with Fisher&#8217;s exact test if a count in any cell was less than 5</p>
###xml 3591 4037 3589 4035 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="18"><sup>a</sup>HER2 IHC with fluorescence in situ hybridization confirmation and IHC for ER and PgR were performed as previously described [<xref ref-type="bibr" rid="CR12">12</xref>]</p><p textid="19"><sup>b</sup>Aromatase protein expression considered positive if any aromatase IHC staining was present</p><p textid="20"><sup>c</sup>For age and clinical tumor size the student&#8217;s <italic>t</italic> test was used to compare the aromatase positive and negative groups. For binary variables the <italic>X</italic><sup>2</sup> test was applied with Fisher&#8217;s exact test if a count in any cell was less than 5</p></table-wrap-foot>
###xml 2388 4037 2388 4035 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="17">Patients and tumors characteristics by location of aromatase protein expression status at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Characteristics</th><th align="left" colspan="4">Aromatase protein expression [<italic>n</italic> (%)]<sup>b</sup></th></tr><tr><th align="left" colspan="2">Tumor epithelial aromatase</th><th align="left" colspan="2">Stromal aromatase</th></tr><tr><th align="left">Negative</th><th align="left">Positive</th><th align="left">Negative</th><th align="left">Positive</th></tr></thead><tbody><tr><td align="left" colspan="5">Treatment</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Tamoxifen</td><td char="." align="left">24 (53%)</td><td char="." align="left">72 (49%)</td><td char="." align="left">29 (54)</td><td char="." align="left">63 (48)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Letrozole</td><td char="." align="left">21 (47%)</td><td char="." align="left">75 (51%)</td><td char="." align="left">25 (46)</td><td char="." align="left">69 (52)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.6102</td><td char="." align="left" colspan="2">0.4605</td></tr><tr><td align="left">Age (year)</td><td char="." align="left">66.8</td><td char="." align="left">67.6</td><td char="." align="left">67.6</td><td char="." align="left">67</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>c</sup></td><td char="." align="left" colspan="2">0.6214</td><td char="." align="left" colspan="2">0.6969</td></tr><tr><td align="left">Clinical tumor size (cm)</td><td char="." align="left">5.7</td><td char="." align="left">4.8</td><td char="." align="left">5.5</td><td char="." align="left">4.7</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>c</sup></td><td char="." align="left" colspan="2">0.0144</td><td char="." align="left" colspan="2">0.0398</td></tr><tr><td align="left" colspan="5">Pre treatment grade</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;I</td><td char="." align="left">4 (10%)</td><td char="." align="left">16 (13%)</td><td char="." align="left">4 (8%)</td><td char="." align="left">16 (15%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;II/III</td><td char="." align="left">38 (90%)</td><td char="." align="left">103 (87%)</td><td char="." align="left">47 (92%)</td><td char="." align="left">90 (85%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.5971</td><td char="." align="left" colspan="2">0.3064</td></tr><tr><td align="left" colspan="5">Pathological tumor size</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;&#8804;20&#160;mm</td><td char="." align="left">11 (27%)</td><td char="." align="left">44 (32%)</td><td char="." align="left">11 (27%)</td><td char="." align="left">44 (32%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;&gt;20&#160;mm</td><td char="." align="left">30 (73%)</td><td char="." align="left">95 (68%)</td><td char="." align="left">30 (73%)</td><td char="." align="left">95 (68%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.5567</td><td char="." align="left" colspan="2">0.5567</td></tr><tr><td align="left" colspan="5">Pathological node status</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">16 (41%)</td><td char="." align="left">55 (43%)</td><td char="." align="left">21 (47%)</td><td char="." align="left">50 (43%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">23 (59%)</td><td char="." align="left">72 (57%)</td><td char="." align="left">24 (53%)</td><td char="." align="left">65 (57%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.8017</td><td char="." align="left" colspan="2">0.7160</td></tr><tr><td align="left" colspan="5">HER2 status<sup>a</sup></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">40 (91%)</td><td char="." align="left">140 (95%)</td><td char="." align="left">50 (93%)</td><td char="." align="left">125 (95%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">4 (9%)</td><td char="." align="left">7 (5%)</td><td char="." align="left">4 (7%)</td><td char="." align="left">6 (5%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.2806</td><td char="." align="left" colspan="2">0.4810</td></tr><tr><td align="left" colspan="5">ER status<sup>c</sup></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">11 (20%)</td><td char="." align="left">12 (8%)</td><td char="." align="left">14 (20%)</td><td char="." align="left">9 (6%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">44 (80%)</td><td char="." align="left">148 (93%)</td><td char="." align="left">55 (80%)</td><td char="." align="left">131 (94%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.0098</td><td char="." align="left" colspan="2">0.0027</td></tr><tr><td align="left" colspan="5">PgR status<sup>c</sup></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative</td><td char="." align="left">16 (36%)</td><td char="." align="left">48 (33%)</td><td char="." align="left">20 (37%)</td><td char="." align="left">43 (33%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="left">28 (64%)</td><td char="." align="left">98 (67%)</td><td char="." align="left">34 (63%)</td><td char="." align="left">87 (67%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.6688</td><td char="." align="left" colspan="2">0.6072</td></tr></tbody></table><table-wrap-foot><p textid="18"><sup>a</sup>HER2 IHC with fluorescence in situ hybridization confirmation and IHC for ER and PgR were performed as previously described [<xref ref-type="bibr" rid="CR12">12</xref>]</p><p textid="19"><sup>b</sup>Aromatase protein expression considered positive if any aromatase IHC staining was present</p><p textid="20"><sup>c</sup>For age and clinical tumor size the student&#8217;s <italic>t</italic> test was used to compare the aromatase positive and negative groups. For binary variables the <italic>X</italic><sup>2</sup> test was applied with Fisher&#8217;s exact test if a count in any cell was less than 5</p></table-wrap-foot></table-wrap>
###xml 1816 1823 <span type="species:ncbi:9606">patient</span>
Initially four cellular components were scored for aromatase expression (fibroblast cells, adipose cells, benign breast duct cells and invasive cancer cells). However benign ducts and adipose tissue were very inconsistently present in the slides available. Thus, only stromal cell scores and invasive cancer cell scores could be adequately studied in terms of correlations with clinical parameters. Ultimately aromatase analysis was conducted on 197 cases in which central analysis confirmed ER+ status and 23 cases in which the ER status was known to be ER negative in the central laboratory (with a cut point of Allred score of 0 or 2 as the definition of negative). Of these 197 ER+ cases, 192 (96 on letrozole, 96 on tamoxifen) had sufficient tumor cells on specimens to qualify for the analysis presented in this report. Aromatase expression SIP score in the stomal cell and tumor cell compartments were highly correlated (Kendall's Tau 0.46, P = 0.0001, Fig. 1a) Tumor cell aromatase SIP score was positively correlated with ER levels as a continuous score (Kendall's Tau P = 0.006, Fig. 1b), however there was no significant correlation with progesterone receptor (PgR) level (data not shown). Finally the aromatase SIP score in the cancer compartment was inversely associated with Ki67 level (Kendall's Tau P = 0.003 Fig. 1c). To examine correlations between aromatase expression and dichotomized clinical variables the aromatase staining score was reduced to simple present or absent categories. Of the variables examined, both stroma and tumor epithelial aromatase expression were associated with smaller clinical tumor size at baseline and ER positive status as a dichotomous variable (Allred 0-2 vs. Allred 3-8) but aromatase status (present vs. absent) did not interact with the other factors examined (patient age, tumor grade, lymph node status, PgR and HER2 status) (Table 1).Fig. 1Correlations between the site of aromatase expression, ER and Ki67 as semi-continuous variables. Box plots comparing the distributions of aromatase SIP scores in stromal cells and cancer cells (a), aromatase SIP scores in cancer cells and ER Allred scores (b) and Ki67 percentage and aromatase SIP scores in cancer cells (c) at baseline. The large boxes stretch from the 25th to 75th percentile, the lines crossing the boxes are medians, the dots are means and the small boxes are outliers.Table 1Patients and tumors characteristics by location of aromatase protein expression status at baselineCharacteristicsAromatase protein expression [n (%)]bTumor epithelial aromataseStromal aromataseNegativePositiveNegativePositiveTreatment    Tamoxifen24 (53%)72 (49%)29 (54)63 (48)    Letrozole21 (47%)75 (51%)25 (46)69 (52)    P-value0.61020.4605Age (year)66.867.667.667    P-valuec0.62140.6969Clinical tumor size (cm)5.74.85.54.7    P-valuec0.01440.0398Pre treatment grade    I4 (10%)16 (13%)4 (8%)16 (15%)    II/III38 (90%)103 (87%)47 (92%)90 (85%)    P-value0.59710.3064Pathological tumor size    </=20 mm11 (27%)44 (32%)11 (27%)44 (32%)    >20 mm30 (73%)95 (68%)30 (73%)95 (68%)    P-value0.55670.5567Pathological node status    Negative16 (41%)55 (43%)21 (47%)50 (43%)    Positive23 (59%)72 (57%)24 (53%)65 (57%)    P-value0.80170.7160HER2 statusa    Negative40 (91%)140 (95%)50 (93%)125 (95%)    Positive4 (9%)7 (5%)4 (7%)6 (5%)    P-value0.28060.4810ER statusc    Negative11 (20%)12 (8%)14 (20%)9 (6%)    Positive44 (80%)148 (93%)55 (80%)131 (94%)    P-value0.00980.0027PgR statusc    Negative16 (36%)48 (33%)20 (37%)43 (33%)    Positive28 (64%)98 (67%)34 (63%)87 (67%)    P-value0.66880.6072aHER2 IHC with fluorescence in situ hybridization confirmation and IHC for ER and PgR were performed as previously described [12]bAromatase protein expression considered positive if any aromatase IHC staining was presentcFor age and clinical tumor size the student's t test was used to compare the aromatase positive and negative groups. For binary variables the X2 test was applied with Fisher's exact test if a count in any cell was less than 5
###end p 15
###begin p 16
###xml 194 195 194 195 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 257 258 257 258 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 322 323 322 323 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
Correlations between the site of aromatase expression, ER and Ki67 as semi-continuous variables. Box plots comparing the distributions of aromatase SIP scores in stromal cells and cancer cells (a), aromatase SIP scores in cancer cells and ER Allred scores (b) and Ki67 percentage and aromatase SIP scores in cancer cells (c) at baseline. The large boxes stretch from the 25th to 75th percentile, the lines crossing the boxes are medians, the dots are means and the small boxes are outliers.
###end p 16
###begin p 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and tumors characteristics by location of aromatase protein expression status at baseline
###end p 17
###begin p 18
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
aHER2 IHC with fluorescence in situ hybridization confirmation and IHC for ER and PgR were performed as previously described [12]
###end p 18
###begin p 19
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bAromatase protein expression considered positive if any aromatase IHC staining was present
###end p 19
###begin p 20
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 47 48 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 143 144 143 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 144 145 144 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
cFor age and clinical tumor size the student's t test was used to compare the aromatase positive and negative groups. For binary variables the X2 test was applied with Fisher's exact test if a count in any cell was less than 5
###end p 20
###begin title 21
Aromatase expression and clinical or radiological response to neoadjuvant letrozole or tamoxifen
###end title 21
###begin p 22
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 721 722 721 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 724 731 724 731 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 731 883 731 883 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="23">Analysis of clinical, mammogram and ultrasound response data according to aromatase protein expression status in tamoxifen or letrozole treated patients</p>
###xml 731 883 731 883 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="23">Analysis of clinical, mammogram and ultrasound response data according to aromatase protein expression status in tamoxifen or letrozole treated patients</p></caption>
###xml 883 892 883 892 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Responses</th>
###xml 922 923 922 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 892 928 892 928 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Aromatase protein expression [<italic>n</italic> (%)]</th>
###xml 883 928 883 928 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="3">Responses</th><th align="left" colspan="4">Aromatase protein expression [<italic>n</italic> (%)]</th></tr>
###xml 928 954 928 954 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Tumor epithelial aromatase</th>
###xml 954 971 954 971 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Stromal aromatase</th>
###xml 928 971 928 971 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="2">Tumor epithelial aromatase</th><th align="left" colspan="2">Stromal aromatase</th></tr>
###xml 971 979 971 979 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</th>
###xml 979 987 979 987 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</th>
###xml 987 995 987 995 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</th>
###xml 995 1003 995 1003 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</th>
###xml 971 1003 971 1003 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Negative</th><th align="left">Positive</th><th align="left">Negative</th><th align="left">Positive</th></tr>
###xml 883 1003 883 1003 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="3">Responses</th><th align="left" colspan="4">Aromatase protein expression [<italic>n</italic> (%)]</th></tr><tr><th align="left" colspan="2">Tumor epithelial aromatase</th><th align="left" colspan="2">Stromal aromatase</th></tr><tr><th align="left">Negative</th><th align="left">Positive</th><th align="left">Negative</th><th align="left">Positive</th></tr></thead>
###xml 1003 1020 1003 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clinical response</italic>
###xml 1020 1021 1020 1021 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1003 1021 1003 1021 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5"><italic>Clinical response</italic><sup>a</sup></td>
###xml 1003 1021 1003 1021 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5"><italic>Clinical response</italic><sup>a</sup></td></tr>
###xml 1021 1035 1021 1035 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Letrozole only</td>
###xml 1021 1035 1021 1035 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Letrozole only</td></tr>
###xml 1035 1041 1035 1041 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;No</td>
###xml 1041 1048 1041 1048 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">6 (29%)</td>
###xml 1048 1056 1048 1056 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">24 (32%)</td>
###xml 1056 1064 1056 1064 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">11 (44%)</td>
###xml 1064 1070 1064 1070 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">18(26)</td>
###xml 1035 1070 1035 1070 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">6 (29%)</td><td char="(" align="left">24 (32%)</td><td char="(" align="left">11 (44%)</td><td char="(" align="left">18(26)</td></tr>
###xml 1070 1077 1070 1077 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Yes</td>
###xml 1077 1085 1077 1085 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">15 (71%)</td>
###xml 1085 1093 1085 1093 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">51 (68%)</td>
###xml 1093 1101 1093 1101 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">14 (56%)</td>
###xml 1101 1107 1101 1107 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">51(74)</td>
###xml 1070 1107 1070 1107 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">15 (71%)</td><td char="(" align="left">51 (68%)</td><td char="(" align="left">14 (56%)</td><td char="(" align="left">51(74)</td></tr>
###xml 1111 1112 1111 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1107 1118 1107 1118 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 1118 1124 1118 1124 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.7657</td>
###xml 1124 1130 1124 1130 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left" colspan="2">0.0984</td>
###xml 1107 1130 1107 1130 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.7657</td><td char="(" align="left" colspan="2">0.0984</td></tr>
###xml 1130 1144 1130 1144 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Tamoxifen only</td>
###xml 1130 1144 1130 1144 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Tamoxifen only</td></tr>
###xml 1144 1150 1144 1150 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;No</td>
###xml 1150 1158 1150 1158 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">12 (50%)</td>
###xml 1158 1166 1158 1166 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">37 (51%)</td>
###xml 1166 1174 1166 1174 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">13 (45%)</td>
###xml 1174 1182 1174 1182 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">34 (54%)</td>
###xml 1144 1182 1144 1182 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">12 (50%)</td><td char="(" align="left">37 (51%)</td><td char="(" align="left">13 (45%)</td><td char="(" align="left">34 (54%)</td></tr>
###xml 1182 1189 1182 1189 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Yes</td>
###xml 1189 1197 1189 1197 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">12 (50%)</td>
###xml 1197 1205 1197 1205 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">35 (49%)</td>
###xml 1205 1213 1205 1213 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">16 (55%)</td>
###xml 1213 1221 1213 1221 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">29 (46%)</td>
###xml 1182 1221 1182 1221 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">12 (50%)</td><td char="(" align="left">35 (49%)</td><td char="(" align="left">16 (55%)</td><td char="(" align="left">29 (46%)</td></tr>
###xml 1225 1226 1225 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1221 1232 1221 1232 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 1232 1238 1232 1238 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.9067</td>
###xml 1238 1244 1238 1244 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left" colspan="2">0.4177</td>
###xml 1221 1244 1221 1244 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.9067</td><td char="(" align="left" colspan="2">0.4177</td></tr>
###xml 1244 1249 1244 1249 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Fused</td>
###xml 1244 1249 1244 1249 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Fused</td></tr>
###xml 1249 1255 1249 1255 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;No</td>
###xml 1255 1263 1255 1263 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">18 (40%)</td>
###xml 1263 1271 1263 1271 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">61 (41%)</td>
###xml 1271 1279 1271 1279 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">24 (44%)</td>
###xml 1279 1287 1279 1287 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">52 (39%)</td>
###xml 1249 1287 1249 1287 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">18 (40%)</td><td char="(" align="left">61 (41%)</td><td char="(" align="left">24 (44%)</td><td char="(" align="left">52 (39%)</td></tr>
###xml 1287 1294 1287 1294 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Yes</td>
###xml 1294 1302 1294 1302 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">27 (60%)</td>
###xml 1302 1310 1302 1310 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">86 (59%)</td>
###xml 1310 1318 1310 1318 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">30 (56%)</td>
###xml 1318 1326 1318 1326 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">80 (61%)</td>
###xml 1287 1326 1287 1326 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">27 (60%)</td><td char="(" align="left">86 (59%)</td><td char="(" align="left">30 (56%)</td><td char="(" align="left">80 (61%)</td></tr>
###xml 1330 1331 1330 1331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1326 1337 1326 1337 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 1337 1343 1337 1343 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.8587</td>
###xml 1343 1349 1343 1349 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left" colspan="2">0.5259</td>
###xml 1326 1349 1326 1349 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.8587</td><td char="(" align="left" colspan="2">0.5259</td></tr>
###xml 1349 1363 1349 1363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mammo response</italic>
###xml 1363 1364 1363 1364 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1349 1364 1349 1364 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5"><italic>Mammo response</italic><sup>a</sup></td>
###xml 1349 1364 1349 1364 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5"><italic>Mammo response</italic><sup>a</sup></td></tr>
###xml 1364 1378 1364 1378 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Letrozole only</td>
###xml 1364 1378 1364 1378 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Letrozole only</td></tr>
###xml 1378 1384 1378 1384 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;No</td>
###xml 1384 1392 1384 1392 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">13 (62%)</td>
###xml 1392 1400 1392 1400 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">47 (63%)</td>
###xml 1400 1408 1400 1408 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">17 (68%)</td>
###xml 1408 1416 1408 1416 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">42 (61%)</td>
###xml 1378 1416 1378 1416 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">13 (62%)</td><td char="(" align="left">47 (63%)</td><td char="." align="left">17 (68%)</td><td char="(" align="left">42 (61%)</td></tr>
###xml 1416 1423 1416 1423 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Yes</td>
###xml 1423 1430 1423 1430 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">8 (38%)</td>
###xml 1430 1438 1430 1438 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">28 (37%)</td>
###xml 1438 1445 1438 1445 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">8 (32%)</td>
###xml 1445 1453 1445 1453 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">27 (39%)</td>
###xml 1416 1453 1416 1453 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">8 (38%)</td><td char="(" align="left">28 (37%)</td><td char="." align="left">8 (32%)</td><td char="(" align="left">27 (39%)</td></tr>
###xml 1457 1458 1457 1458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1453 1464 1453 1464 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 1464 1470 1464 1470 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.9494</td>
###xml 1470 1476 1470 1476 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.5297</td>
###xml 1453 1476 1453 1476 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.9494</td><td char="." align="left" colspan="2">0.5297</td></tr>
###xml 1476 1490 1476 1490 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Tamoxifen only</td>
###xml 1476 1490 1476 1490 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Tamoxifen only</td></tr>
###xml 1490 1496 1490 1496 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;No</td>
###xml 1496 1504 1496 1504 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">19 (79%)</td>
###xml 1504 1512 1504 1512 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">54 (75%)</td>
###xml 1512 1520 1512 1520 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">23 (79%)</td>
###xml 1520 1528 1520 1528 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">48 (76%)</td>
###xml 1490 1528 1490 1528 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">19 (79%)</td><td char="(" align="left">54 (75%)</td><td char="." align="left">23 (79%)</td><td char="(" align="left">48 (76%)</td></tr>
###xml 1528 1535 1528 1535 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Yes</td>
###xml 1535 1542 1535 1542 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">5 (21%)</td>
###xml 1542 1550 1542 1550 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">18 (25%)</td>
###xml 1550 1557 1550 1557 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">6 (21%)</td>
###xml 1557 1565 1557 1565 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">15 (24%)</td>
###xml 1528 1565 1528 1565 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">5 (21%)</td><td char="(" align="left">18 (25%)</td><td char="." align="left">6 (21%)</td><td char="(" align="left">15 (24%)</td></tr>
###xml 1569 1570 1569 1570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1565 1576 1565 1576 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 1576 1582 1576 1582 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.6803</td>
###xml 1582 1588 1582 1588 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.7418</td>
###xml 1565 1588 1565 1588 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.6803</td><td char="." align="left" colspan="2">0.7418</td></tr>
###xml 1588 1593 1588 1593 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Fused</td>
###xml 1588 1593 1588 1593 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Fused</td></tr>
###xml 1593 1599 1593 1599 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;No</td>
###xml 1599 1607 1599 1607 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">32 (71%)</td>
###xml 1607 1616 1607 1616 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">101 (69%)</td>
###xml 1616 1624 1616 1624 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">40 (74%)</td>
###xml 1624 1632 1624 1632 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">90 (68%)</td>
###xml 1593 1632 1593 1632 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">32 (71%)</td><td char="(" align="left">101 (69%)</td><td char="." align="left">40 (74%)</td><td char="(" align="left">90 (68%)</td></tr>
###xml 1632 1639 1632 1639 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Yes</td>
###xml 1639 1647 1639 1647 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">13 (29%)</td>
###xml 1647 1655 1647 1655 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">46 (31%)</td>
###xml 1655 1663 1655 1663 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">14 (26%)</td>
###xml 1663 1671 1663 1671 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">42 (32%)</td>
###xml 1632 1671 1632 1671 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">13 (29%)</td><td char="(" align="left">46 (31%)</td><td char="." align="left">14 (26%)</td><td char="(" align="left">42 (32%)</td></tr>
###xml 1675 1676 1675 1676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1671 1682 1671 1682 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 1682 1688 1682 1688 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.7604</td>
###xml 1688 1694 1688 1694 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.4278</td>
###xml 1671 1694 1671 1694 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.7604</td><td char="." align="left" colspan="2">0.4278</td></tr>
###xml 1694 1713 1694 1713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ultrasound response</italic>
###xml 1713 1714 1713 1714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1694 1714 1694 1714 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5"><italic>Ultrasound response</italic><sup>a</sup></td>
###xml 1694 1714 1694 1714 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5"><italic>Ultrasound response</italic><sup>a</sup></td></tr>
###xml 1714 1728 1714 1728 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Letrozole only</td>
###xml 1714 1728 1714 1728 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Letrozole only</td></tr>
###xml 1728 1734 1728 1734 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;No</td>
###xml 1734 1742 1734 1742 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">12 (67%)</td>
###xml 1742 1750 1742 1750 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">39 (56%)</td>
###xml 1750 1758 1750 1758 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">16 (73%)</td>
###xml 1758 1766 1758 1766 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">34 (52%)</td>
###xml 1728 1766 1728 1766 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">12 (67%)</td><td char="(" align="left">39 (56%)</td><td char="." align="left">16 (73%)</td><td char="(" align="left">34 (52%)</td></tr>
###xml 1766 1773 1766 1773 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Yes</td>
###xml 1773 1780 1773 1780 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">6 (33%)</td>
###xml 1780 1788 1780 1788 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">31 (44%)</td>
###xml 1788 1795 1788 1795 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">6 (27%)</td>
###xml 1795 1803 1795 1803 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">31 (48%)</td>
###xml 1766 1803 1766 1803 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">6 (33%)</td><td char="(" align="left">31 (44%)</td><td char="." align="left">6 (27%)</td><td char="(" align="left">31 (48%)</td></tr>
###xml 1807 1808 1807 1808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1803 1814 1803 1814 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 1814 1820 1814 1820 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.4038</td>
###xml 1820 1826 1820 1826 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.0959</td>
###xml 1803 1826 1803 1826 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.4038</td><td char="." align="left" colspan="2">0.0959</td></tr>
###xml 1826 1840 1826 1840 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Tamoxifen only</td>
###xml 1826 1840 1826 1840 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Tamoxifen only</td></tr>
###xml 1840 1846 1840 1846 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;No</td>
###xml 1846 1854 1846 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">13 (68%)</td>
###xml 1854 1862 1854 1862 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">44 (64%)</td>
###xml 1862 1870 1862 1870 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">15 (60%)</td>
###xml 1870 1878 1870 1878 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">41 (69%)</td>
###xml 1840 1878 1840 1878 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">13 (68%)</td><td char="(" align="left">44 (64%)</td><td char="." align="left">15 (60%)</td><td char="(" align="left">41 (69%)</td></tr>
###xml 1878 1885 1878 1885 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Yes</td>
###xml 1885 1892 1885 1892 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">6 (32%)</td>
###xml 1892 1900 1892 1900 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">25 (36%)</td>
###xml 1900 1908 1900 1908 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">10 (60%)</td>
###xml 1908 1916 1908 1916 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">18 (31%)</td>
###xml 1878 1916 1878 1916 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">6 (32%)</td><td char="(" align="left">25 (36%)</td><td char="." align="left">10 (60%)</td><td char="(" align="left">18 (31%)</td></tr>
###xml 1920 1921 1920 1921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1916 1927 1916 1927 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 1927 1933 1927 1933 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.7085</td>
###xml 1933 1939 1933 1939 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.4016</td>
###xml 1916 1939 1916 1939 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.7085</td><td char="." align="left" colspan="2">0.4016</td></tr>
###xml 1939 1944 1939 1944 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Fused</td>
###xml 1939 1944 1939 1944 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Fused</td></tr>
###xml 1944 1950 1944 1950 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;No</td>
###xml 1950 1958 1950 1958 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">25 (68%)</td>
###xml 1958 1966 1958 1966 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">83 (60%)</td>
###xml 1966 1974 1966 1974 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">31 (66%)</td>
###xml 1974 1982 1974 1982 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">75 (60%)</td>
###xml 1944 1982 1944 1982 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">25 (68%)</td><td align="left">83 (60%)</td><td char="." align="left">31 (66%)</td><td char="(" align="left">75 (60%)</td></tr>
###xml 1982 1989 1982 1989 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Yes</td>
###xml 1989 1997 1989 1997 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">12 (32%)</td>
###xml 1997 2005 1997 2005 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">56 (40%)</td>
###xml 2005 2013 2005 2013 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">16 (34%)</td>
###xml 2013 2021 2013 2021 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="left">49 (40%)</td>
###xml 1982 2021 1982 2021 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">12 (32%)</td><td align="left">56 (40%)</td><td char="." align="left">16 (34%)</td><td char="(" align="left">49 (40%)</td></tr>
###xml 2025 2026 2025 2026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2021 2032 2021 2032 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td>
###xml 2032 2038 2032 2038 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.3845</td>
###xml 2038 2044 2038 2044 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left" colspan="2">0.5116</td>
###xml 2021 2044 2021 2044 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.3845</td><td char="." align="left" colspan="2">0.5116</td></tr>
###xml 1003 2044 1003 2044 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" colspan="5"><italic>Clinical response</italic><sup>a</sup></td></tr><tr><td align="left" colspan="5">Letrozole only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">6 (29%)</td><td char="(" align="left">24 (32%)</td><td char="(" align="left">11 (44%)</td><td char="(" align="left">18(26)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">15 (71%)</td><td char="(" align="left">51 (68%)</td><td char="(" align="left">14 (56%)</td><td char="(" align="left">51(74)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.7657</td><td char="(" align="left" colspan="2">0.0984</td></tr><tr><td align="left" colspan="5">Tamoxifen only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">12 (50%)</td><td char="(" align="left">37 (51%)</td><td char="(" align="left">13 (45%)</td><td char="(" align="left">34 (54%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">12 (50%)</td><td char="(" align="left">35 (49%)</td><td char="(" align="left">16 (55%)</td><td char="(" align="left">29 (46%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.9067</td><td char="(" align="left" colspan="2">0.4177</td></tr><tr><td align="left" colspan="5">Fused</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">18 (40%)</td><td char="(" align="left">61 (41%)</td><td char="(" align="left">24 (44%)</td><td char="(" align="left">52 (39%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">27 (60%)</td><td char="(" align="left">86 (59%)</td><td char="(" align="left">30 (56%)</td><td char="(" align="left">80 (61%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.8587</td><td char="(" align="left" colspan="2">0.5259</td></tr><tr><td align="left" colspan="5"><italic>Mammo response</italic><sup>a</sup></td></tr><tr><td align="left" colspan="5">Letrozole only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">13 (62%)</td><td char="(" align="left">47 (63%)</td><td char="." align="left">17 (68%)</td><td char="(" align="left">42 (61%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">8 (38%)</td><td char="(" align="left">28 (37%)</td><td char="." align="left">8 (32%)</td><td char="(" align="left">27 (39%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.9494</td><td char="." align="left" colspan="2">0.5297</td></tr><tr><td align="left" colspan="5">Tamoxifen only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">19 (79%)</td><td char="(" align="left">54 (75%)</td><td char="." align="left">23 (79%)</td><td char="(" align="left">48 (76%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">5 (21%)</td><td char="(" align="left">18 (25%)</td><td char="." align="left">6 (21%)</td><td char="(" align="left">15 (24%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.6803</td><td char="." align="left" colspan="2">0.7418</td></tr><tr><td align="left" colspan="5">Fused</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">32 (71%)</td><td char="(" align="left">101 (69%)</td><td char="." align="left">40 (74%)</td><td char="(" align="left">90 (68%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">13 (29%)</td><td char="(" align="left">46 (31%)</td><td char="." align="left">14 (26%)</td><td char="(" align="left">42 (32%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.7604</td><td char="." align="left" colspan="2">0.4278</td></tr><tr><td align="left" colspan="5"><italic>Ultrasound response</italic><sup>a</sup></td></tr><tr><td align="left" colspan="5">Letrozole only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">12 (67%)</td><td char="(" align="left">39 (56%)</td><td char="." align="left">16 (73%)</td><td char="(" align="left">34 (52%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">6 (33%)</td><td char="(" align="left">31 (44%)</td><td char="." align="left">6 (27%)</td><td char="(" align="left">31 (48%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.4038</td><td char="." align="left" colspan="2">0.0959</td></tr><tr><td align="left" colspan="5">Tamoxifen only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">13 (68%)</td><td char="(" align="left">44 (64%)</td><td char="." align="left">15 (60%)</td><td char="(" align="left">41 (69%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">6 (32%)</td><td char="(" align="left">25 (36%)</td><td char="." align="left">10 (60%)</td><td char="(" align="left">18 (31%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.7085</td><td char="." align="left" colspan="2">0.4016</td></tr><tr><td align="left" colspan="5">Fused</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">25 (68%)</td><td align="left">83 (60%)</td><td char="." align="left">31 (66%)</td><td char="(" align="left">75 (60%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">12 (32%)</td><td align="left">56 (40%)</td><td char="." align="left">16 (34%)</td><td char="(" align="left">49 (40%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.3845</td><td char="." align="left" colspan="2">0.5116</td></tr></tbody>
###xml 883 2044 883 2044 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Responses</th><th align="left" colspan="4">Aromatase protein expression [<italic>n</italic> (%)]</th></tr><tr><th align="left" colspan="2">Tumor epithelial aromatase</th><th align="left" colspan="2">Stromal aromatase</th></tr><tr><th align="left">Negative</th><th align="left">Positive</th><th align="left">Negative</th><th align="left">Positive</th></tr></thead><tbody><tr><td align="left" colspan="5"><italic>Clinical response</italic><sup>a</sup></td></tr><tr><td align="left" colspan="5">Letrozole only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">6 (29%)</td><td char="(" align="left">24 (32%)</td><td char="(" align="left">11 (44%)</td><td char="(" align="left">18(26)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">15 (71%)</td><td char="(" align="left">51 (68%)</td><td char="(" align="left">14 (56%)</td><td char="(" align="left">51(74)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.7657</td><td char="(" align="left" colspan="2">0.0984</td></tr><tr><td align="left" colspan="5">Tamoxifen only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">12 (50%)</td><td char="(" align="left">37 (51%)</td><td char="(" align="left">13 (45%)</td><td char="(" align="left">34 (54%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">12 (50%)</td><td char="(" align="left">35 (49%)</td><td char="(" align="left">16 (55%)</td><td char="(" align="left">29 (46%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.9067</td><td char="(" align="left" colspan="2">0.4177</td></tr><tr><td align="left" colspan="5">Fused</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">18 (40%)</td><td char="(" align="left">61 (41%)</td><td char="(" align="left">24 (44%)</td><td char="(" align="left">52 (39%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">27 (60%)</td><td char="(" align="left">86 (59%)</td><td char="(" align="left">30 (56%)</td><td char="(" align="left">80 (61%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.8587</td><td char="(" align="left" colspan="2">0.5259</td></tr><tr><td align="left" colspan="5"><italic>Mammo response</italic><sup>a</sup></td></tr><tr><td align="left" colspan="5">Letrozole only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">13 (62%)</td><td char="(" align="left">47 (63%)</td><td char="." align="left">17 (68%)</td><td char="(" align="left">42 (61%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">8 (38%)</td><td char="(" align="left">28 (37%)</td><td char="." align="left">8 (32%)</td><td char="(" align="left">27 (39%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.9494</td><td char="." align="left" colspan="2">0.5297</td></tr><tr><td align="left" colspan="5">Tamoxifen only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">19 (79%)</td><td char="(" align="left">54 (75%)</td><td char="." align="left">23 (79%)</td><td char="(" align="left">48 (76%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">5 (21%)</td><td char="(" align="left">18 (25%)</td><td char="." align="left">6 (21%)</td><td char="(" align="left">15 (24%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.6803</td><td char="." align="left" colspan="2">0.7418</td></tr><tr><td align="left" colspan="5">Fused</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">32 (71%)</td><td char="(" align="left">101 (69%)</td><td char="." align="left">40 (74%)</td><td char="(" align="left">90 (68%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">13 (29%)</td><td char="(" align="left">46 (31%)</td><td char="." align="left">14 (26%)</td><td char="(" align="left">42 (32%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.7604</td><td char="." align="left" colspan="2">0.4278</td></tr><tr><td align="left" colspan="5"><italic>Ultrasound response</italic><sup>a</sup></td></tr><tr><td align="left" colspan="5">Letrozole only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">12 (67%)</td><td char="(" align="left">39 (56%)</td><td char="." align="left">16 (73%)</td><td char="(" align="left">34 (52%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">6 (33%)</td><td char="(" align="left">31 (44%)</td><td char="." align="left">6 (27%)</td><td char="(" align="left">31 (48%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.4038</td><td char="." align="left" colspan="2">0.0959</td></tr><tr><td align="left" colspan="5">Tamoxifen only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">13 (68%)</td><td char="(" align="left">44 (64%)</td><td char="." align="left">15 (60%)</td><td char="(" align="left">41 (69%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">6 (32%)</td><td char="(" align="left">25 (36%)</td><td char="." align="left">10 (60%)</td><td char="(" align="left">18 (31%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.7085</td><td char="." align="left" colspan="2">0.4016</td></tr><tr><td align="left" colspan="5">Fused</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">25 (68%)</td><td align="left">83 (60%)</td><td char="." align="left">31 (66%)</td><td char="(" align="left">75 (60%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">12 (32%)</td><td align="left">56 (40%)</td><td char="." align="left">16 (34%)</td><td char="(" align="left">49 (40%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.3845</td><td char="." align="left" colspan="2">0.5116</td></tr></tbody></table>
###xml 2044 2130 2044 2130 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24">Response rate refers to the percentage of patients with a complete or partial response</p>
###xml 2130 2131 2130 2131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2199 2201 2199 2201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 2208 2209 2208 2209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 2209 2210 2209 2210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2130 2291 2130 2291 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25"><sup>a</sup>Response definitions by WHO criteria have been previously reported [<xref ref-type="bibr" rid="CR11">11</xref>]. The <italic>X</italic><sup>2</sup> test was applied with Fisher&#8217;s exact test if a count in any cell was less than 5</p>
###xml 2044 2291 2044 2291 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24">Response rate refers to the percentage of patients with a complete or partial response</p><p textid="25"><sup>a</sup>Response definitions by WHO criteria have been previously reported [<xref ref-type="bibr" rid="CR11">11</xref>]. The <italic>X</italic><sup>2</sup> test was applied with Fisher&#8217;s exact test if a count in any cell was less than 5</p></table-wrap-foot>
###xml 724 2291 724 2291 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="23">Analysis of clinical, mammogram and ultrasound response data according to aromatase protein expression status in tamoxifen or letrozole treated patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Responses</th><th align="left" colspan="4">Aromatase protein expression [<italic>n</italic> (%)]</th></tr><tr><th align="left" colspan="2">Tumor epithelial aromatase</th><th align="left" colspan="2">Stromal aromatase</th></tr><tr><th align="left">Negative</th><th align="left">Positive</th><th align="left">Negative</th><th align="left">Positive</th></tr></thead><tbody><tr><td align="left" colspan="5"><italic>Clinical response</italic><sup>a</sup></td></tr><tr><td align="left" colspan="5">Letrozole only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">6 (29%)</td><td char="(" align="left">24 (32%)</td><td char="(" align="left">11 (44%)</td><td char="(" align="left">18(26)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">15 (71%)</td><td char="(" align="left">51 (68%)</td><td char="(" align="left">14 (56%)</td><td char="(" align="left">51(74)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.7657</td><td char="(" align="left" colspan="2">0.0984</td></tr><tr><td align="left" colspan="5">Tamoxifen only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">12 (50%)</td><td char="(" align="left">37 (51%)</td><td char="(" align="left">13 (45%)</td><td char="(" align="left">34 (54%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">12 (50%)</td><td char="(" align="left">35 (49%)</td><td char="(" align="left">16 (55%)</td><td char="(" align="left">29 (46%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.9067</td><td char="(" align="left" colspan="2">0.4177</td></tr><tr><td align="left" colspan="5">Fused</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">18 (40%)</td><td char="(" align="left">61 (41%)</td><td char="(" align="left">24 (44%)</td><td char="(" align="left">52 (39%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">27 (60%)</td><td char="(" align="left">86 (59%)</td><td char="(" align="left">30 (56%)</td><td char="(" align="left">80 (61%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.8587</td><td char="(" align="left" colspan="2">0.5259</td></tr><tr><td align="left" colspan="5"><italic>Mammo response</italic><sup>a</sup></td></tr><tr><td align="left" colspan="5">Letrozole only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">13 (62%)</td><td char="(" align="left">47 (63%)</td><td char="." align="left">17 (68%)</td><td char="(" align="left">42 (61%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">8 (38%)</td><td char="(" align="left">28 (37%)</td><td char="." align="left">8 (32%)</td><td char="(" align="left">27 (39%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.9494</td><td char="." align="left" colspan="2">0.5297</td></tr><tr><td align="left" colspan="5">Tamoxifen only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">19 (79%)</td><td char="(" align="left">54 (75%)</td><td char="." align="left">23 (79%)</td><td char="(" align="left">48 (76%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">5 (21%)</td><td char="(" align="left">18 (25%)</td><td char="." align="left">6 (21%)</td><td char="(" align="left">15 (24%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.6803</td><td char="." align="left" colspan="2">0.7418</td></tr><tr><td align="left" colspan="5">Fused</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">32 (71%)</td><td char="(" align="left">101 (69%)</td><td char="." align="left">40 (74%)</td><td char="(" align="left">90 (68%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">13 (29%)</td><td char="(" align="left">46 (31%)</td><td char="." align="left">14 (26%)</td><td char="(" align="left">42 (32%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.7604</td><td char="." align="left" colspan="2">0.4278</td></tr><tr><td align="left" colspan="5"><italic>Ultrasound response</italic><sup>a</sup></td></tr><tr><td align="left" colspan="5">Letrozole only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">12 (67%)</td><td char="(" align="left">39 (56%)</td><td char="." align="left">16 (73%)</td><td char="(" align="left">34 (52%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">6 (33%)</td><td char="(" align="left">31 (44%)</td><td char="." align="left">6 (27%)</td><td char="(" align="left">31 (48%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.4038</td><td char="." align="left" colspan="2">0.0959</td></tr><tr><td align="left" colspan="5">Tamoxifen only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">13 (68%)</td><td char="(" align="left">44 (64%)</td><td char="." align="left">15 (60%)</td><td char="(" align="left">41 (69%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">6 (32%)</td><td char="(" align="left">25 (36%)</td><td char="." align="left">10 (60%)</td><td char="(" align="left">18 (31%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.7085</td><td char="." align="left" colspan="2">0.4016</td></tr><tr><td align="left" colspan="5">Fused</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;No</td><td char="." align="left">25 (68%)</td><td align="left">83 (60%)</td><td char="." align="left">31 (66%)</td><td char="(" align="left">75 (60%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Yes</td><td char="." align="left">12 (32%)</td><td align="left">56 (40%)</td><td char="." align="left">16 (34%)</td><td char="(" align="left">49 (40%)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value</td><td char="." align="left" colspan="2">0.3845</td><td char="." align="left" colspan="2">0.5116</td></tr></tbody></table><table-wrap-foot><p textid="24">Response rate refers to the percentage of patients with a complete or partial response</p><p textid="25"><sup>a</sup>Response definitions by WHO criteria have been previously reported [<xref ref-type="bibr" rid="CR11">11</xref>]. The <italic>X</italic><sup>2</sup> test was applied with Fisher&#8217;s exact test if a count in any cell was less than 5</p></table-wrap-foot></table-wrap>
###xml 2291 2298 2291 2298 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 2298 2445 2298 2445 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26">Paired Ki67 data before and after letrozole/tamoxifen therapy according to aromatase protein expression status in breast cancer cells/stromal cells</p>
###xml 2298 2445 2298 2445 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="26">Paired Ki67 data before and after letrozole/tamoxifen therapy according to aromatase protein expression status in breast cancer cells/stromal cells</p></caption>
###xml 2475 2476 2475 2476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2445 2476 2445 2476 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Ki67 [Geometric mean (95% CI)]<sup>a</sup></th>
###xml 2476 2504 2476 2504 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Aromatase protein expression</th>
###xml 2445 2504 2445 2504 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="3">Ki67 [Geometric mean (95% CI)]<sup>a</sup></th><th align="left" colspan="4">Aromatase protein expression</th></tr>
###xml 2504 2516 2504 2516 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Cancer cells</th>
###xml 2516 2529 2516 2529 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Stromal cells</th>
###xml 2504 2529 2504 2529 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="2">Cancer cells</th><th align="left" colspan="2">Stromal cells</th></tr>
###xml 2529 2537 2529 2537 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</th>
###xml 2537 2545 2537 2545 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</th>
###xml 2545 2553 2545 2553 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</th>
###xml 2553 2561 2553 2561 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</th>
###xml 2529 2561 2529 2561 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Negative</th><th align="left">Positive</th><th align="left">Negative</th><th align="left">Positive</th></tr>
###xml 2445 2561 2445 2561 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="3">Ki67 [Geometric mean (95% CI)]<sup>a</sup></th><th align="left" colspan="4">Aromatase protein expression</th></tr><tr><th align="left" colspan="2">Cancer cells</th><th align="left" colspan="2">Stromal cells</th></tr><tr><th align="left">Negative</th><th align="left">Positive</th><th align="left">Negative</th><th align="left">Positive</th></tr></thead>
###xml 2561 2575 2561 2575 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Letrozole only</td>
###xml 2561 2575 2561 2575 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Letrozole only</td></tr>
###xml 2575 2582 2575 2582 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Pre</td>
###xml 2582 2599 2582 2599 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.54 (2.54&#8211;12.08)</td>
###xml 2599 2615 2599 2615 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.56 (2.47&#8211;5.14)</td>
###xml 2615 2631 2615 2631 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.64 (1.70&#8211;7.82)</td>
###xml 2631 2647 2631 2647 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.92 (2.69&#8211;5.72)</td>
###xml 2575 2647 2575 2647 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Pre</td><td char="." align="char">5.54 (2.54&#8211;12.08)</td><td char="." align="char">3.56 (2.47&#8211;5.14)</td><td char="." align="char">3.64 (1.70&#8211;7.82)</td><td char="." align="char">3.92 (2.69&#8211;5.72)</td></tr>
###xml 2647 2655 2647 2655 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Post</td>
###xml 2655 2671 2655 2671 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.70 (0.33&#8211;1.49)</td>
###xml 2671 2687 2671 2687 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.49 (0.31&#8211;0.75)</td>
###xml 2687 2703 2687 2703 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.88 (0.38&#8211;2.04)</td>
###xml 2703 2719 2703 2719 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.44 (0.29&#8211;0.68)</td>
###xml 2647 2719 2647 2719 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Post</td><td char="." align="char">0.70 (0.33&#8211;1.49)</td><td char="." align="char">0.49 (0.31&#8211;0.75)</td><td char="." align="char">0.88 (0.38&#8211;2.04)</td><td char="." align="char">0.44 (0.29&#8211;0.68)</td></tr>
###xml 2723 2724 2723 2724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2730 2731 2730 2731 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2719 2731 2719 2731 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>b</sup></td>
###xml 2731 2737 2731 2737 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0037</td>
###xml 2737 2743 2737 2743 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0001</td>
###xml 2743 2749 2743 2749 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0083</td>
###xml 2749 2755 2749 2755 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0001</td>
###xml 2719 2755 2719 2755 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>b</sup></td><td char="." align="char">0.0037</td><td char="." align="char">0.0001</td><td char="." align="char">0.0083</td><td char="." align="char">0.0001</td></tr>
###xml 2755 2769 2755 2769 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Tamoxifen only</td>
###xml 2755 2769 2755 2769 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Tamoxifen only</td></tr>
###xml 2769 2776 2769 2776 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Pre</td>
###xml 2776 2793 2776 2793 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.97 (3.17&#8211;11.24)</td>
###xml 2793 2809 2793 2809 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.63 (4.18&#8211;7.58)</td>
###xml 2809 2826 2809 2826 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.75 (4.46&#8211;13.47)</td>
###xml 2826 2842 2826 2842 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.67 (3.39&#8211;6.44)</td>
###xml 2769 2842 2769 2842 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Pre</td><td char="." align="char">5.97 (3.17&#8211;11.24)</td><td char="." align="char">5.63 (4.18&#8211;7.58)</td><td char="." align="char">7.75 (4.46&#8211;13.47)</td><td char="." align="char">4.67 (3.39&#8211;6.44)</td></tr>
###xml 2842 2850 2842 2850 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Post</td>
###xml 2850 2866 2850 2866 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.72 (0.75&#8211;3.97)</td>
###xml 2866 2882 2866 2882 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.36 (0.88&#8211;2.09)</td>
###xml 2882 2898 2882 2898 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.61 (0.76&#8211;3.39)</td>
###xml 2898 2914 2898 2914 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.23 (0.77&#8211;1.95)</td>
###xml 2842 2914 2842 2914 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Post</td><td char="." align="char">1.72 (0.75&#8211;3.97)</td><td char="." align="char">1.36 (0.88&#8211;2.09)</td><td char="." align="char">1.61 (0.76&#8211;3.39)</td><td char="." align="char">1.23 (0.77&#8211;1.95)</td></tr>
###xml 2918 2919 2918 2919 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2925 2926 2925 2926 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2914 2926 2914 2926 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>b</sup></td>
###xml 2926 2932 2926 2932 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0117</td>
###xml 2932 2938 2932 2938 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0001</td>
###xml 2938 2944 2938 2944 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0007</td>
###xml 2944 2950 2944 2950 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0001</td>
###xml 2914 2950 2914 2950 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>b</sup></td><td char="." align="char">0.0117</td><td char="." align="char">0.0001</td><td char="." align="char">0.0007</td><td char="." align="char">0.0001</td></tr>
###xml 2561 2950 2561 2950 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" colspan="5">Letrozole only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Pre</td><td char="." align="char">5.54 (2.54&#8211;12.08)</td><td char="." align="char">3.56 (2.47&#8211;5.14)</td><td char="." align="char">3.64 (1.70&#8211;7.82)</td><td char="." align="char">3.92 (2.69&#8211;5.72)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Post</td><td char="." align="char">0.70 (0.33&#8211;1.49)</td><td char="." align="char">0.49 (0.31&#8211;0.75)</td><td char="." align="char">0.88 (0.38&#8211;2.04)</td><td char="." align="char">0.44 (0.29&#8211;0.68)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>b</sup></td><td char="." align="char">0.0037</td><td char="." align="char">0.0001</td><td char="." align="char">0.0083</td><td char="." align="char">0.0001</td></tr><tr><td align="left" colspan="5">Tamoxifen only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Pre</td><td char="." align="char">5.97 (3.17&#8211;11.24)</td><td char="." align="char">5.63 (4.18&#8211;7.58)</td><td char="." align="char">7.75 (4.46&#8211;13.47)</td><td char="." align="char">4.67 (3.39&#8211;6.44)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Post</td><td char="." align="char">1.72 (0.75&#8211;3.97)</td><td char="." align="char">1.36 (0.88&#8211;2.09)</td><td char="." align="char">1.61 (0.76&#8211;3.39)</td><td char="." align="char">1.23 (0.77&#8211;1.95)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>b</sup></td><td char="." align="char">0.0117</td><td char="." align="char">0.0001</td><td char="." align="char">0.0007</td><td char="." align="char">0.0001</td></tr></tbody>
###xml 2445 2950 2445 2950 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Ki67 [Geometric mean (95% CI)]<sup>a</sup></th><th align="left" colspan="4">Aromatase protein expression</th></tr><tr><th align="left" colspan="2">Cancer cells</th><th align="left" colspan="2">Stromal cells</th></tr><tr><th align="left">Negative</th><th align="left">Positive</th><th align="left">Negative</th><th align="left">Positive</th></tr></thead><tbody><tr><td align="left" colspan="5">Letrozole only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Pre</td><td char="." align="char">5.54 (2.54&#8211;12.08)</td><td char="." align="char">3.56 (2.47&#8211;5.14)</td><td char="." align="char">3.64 (1.70&#8211;7.82)</td><td char="." align="char">3.92 (2.69&#8211;5.72)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Post</td><td char="." align="char">0.70 (0.33&#8211;1.49)</td><td char="." align="char">0.49 (0.31&#8211;0.75)</td><td char="." align="char">0.88 (0.38&#8211;2.04)</td><td char="." align="char">0.44 (0.29&#8211;0.68)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>b</sup></td><td char="." align="char">0.0037</td><td char="." align="char">0.0001</td><td char="." align="char">0.0083</td><td char="." align="char">0.0001</td></tr><tr><td align="left" colspan="5">Tamoxifen only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Pre</td><td char="." align="char">5.97 (3.17&#8211;11.24)</td><td char="." align="char">5.63 (4.18&#8211;7.58)</td><td char="." align="char">7.75 (4.46&#8211;13.47)</td><td char="." align="char">4.67 (3.39&#8211;6.44)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Post</td><td char="." align="char">1.72 (0.75&#8211;3.97)</td><td char="." align="char">1.36 (0.88&#8211;2.09)</td><td char="." align="char">1.61 (0.76&#8211;3.39)</td><td char="." align="char">1.23 (0.77&#8211;1.95)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>b</sup></td><td char="." align="char">0.0117</td><td char="." align="char">0.0001</td><td char="." align="char">0.0007</td><td char="." align="char">0.0001</td></tr></tbody></table>
###xml 2950 2951 2950 2951 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2950 2978 2950 2978 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27"><sup>a</sup>95% CI: confidence Interval</p>
###xml 2978 2979 2978 2979 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2978 3098 2978 3098 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28"><sup>b</sup>Wilcoxon signed rank test was used to compare paired Ki67 data within each group defined by aromatase expression status</p>
###xml 2950 3098 2950 3098 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27"><sup>a</sup>95% CI: confidence Interval</p><p textid="28"><sup>b</sup>Wilcoxon signed rank test was used to compare paired Ki67 data within each group defined by aromatase expression status</p></table-wrap-foot>
###xml 2291 3098 2291 3098 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="26">Paired Ki67 data before and after letrozole/tamoxifen therapy according to aromatase protein expression status in breast cancer cells/stromal cells</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Ki67 [Geometric mean (95% CI)]<sup>a</sup></th><th align="left" colspan="4">Aromatase protein expression</th></tr><tr><th align="left" colspan="2">Cancer cells</th><th align="left" colspan="2">Stromal cells</th></tr><tr><th align="left">Negative</th><th align="left">Positive</th><th align="left">Negative</th><th align="left">Positive</th></tr></thead><tbody><tr><td align="left" colspan="5">Letrozole only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Pre</td><td char="." align="char">5.54 (2.54&#8211;12.08)</td><td char="." align="char">3.56 (2.47&#8211;5.14)</td><td char="." align="char">3.64 (1.70&#8211;7.82)</td><td char="." align="char">3.92 (2.69&#8211;5.72)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Post</td><td char="." align="char">0.70 (0.33&#8211;1.49)</td><td char="." align="char">0.49 (0.31&#8211;0.75)</td><td char="." align="char">0.88 (0.38&#8211;2.04)</td><td char="." align="char">0.44 (0.29&#8211;0.68)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>b</sup></td><td char="." align="char">0.0037</td><td char="." align="char">0.0001</td><td char="." align="char">0.0083</td><td char="." align="char">0.0001</td></tr><tr><td align="left" colspan="5">Tamoxifen only</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Pre</td><td char="." align="char">5.97 (3.17&#8211;11.24)</td><td char="." align="char">5.63 (4.18&#8211;7.58)</td><td char="." align="char">7.75 (4.46&#8211;13.47)</td><td char="." align="char">4.67 (3.39&#8211;6.44)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Post</td><td char="." align="char">1.72 (0.75&#8211;3.97)</td><td char="." align="char">1.36 (0.88&#8211;2.09)</td><td char="." align="char">1.61 (0.76&#8211;3.39)</td><td char="." align="char">1.23 (0.77&#8211;1.95)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;<italic>P</italic>-value<sup>b</sup></td><td char="." align="char">0.0117</td><td char="." align="char">0.0001</td><td char="." align="char">0.0007</td><td char="." align="char">0.0001</td></tr></tbody></table><table-wrap-foot><p textid="27"><sup>a</sup>95% CI: confidence Interval</p><p textid="28"><sup>b</sup>Wilcoxon signed rank test was used to compare paired Ki67 data within each group defined by aromatase expression status</p></table-wrap-foot></table-wrap>
###xml 2086 2094 <span type="species:ncbi:9606">patients</span>
A series of contingency tables were examined to identify interactions between aromatase expression status and response (Table 2). In the P024 study, response was recorded according to clinical measurements, ultrasound and mammography. There was no evidence of interactions with any of the response definitions, whether the stroma or the tumor cell aromatase status was examined as the interacting factor or whether letrozole or tamoxifen treated cases were considered separately. Consistent with a lack of an influence on endocrine therapy responsiveness, there was no interaction with treatment-induced changes in Ki67 or absolute post-treatment Ki67 levels in either tamoxifen or letrozole-treated tumor samples (Table 3).Table 2Analysis of clinical, mammogram and ultrasound response data according to aromatase protein expression status in tamoxifen or letrozole treated patientsResponsesAromatase protein expression [n (%)]Tumor epithelial aromataseStromal aromataseNegativePositiveNegativePositiveClinical responseaLetrozole only    No6 (29%)24 (32%)11 (44%)18(26)    Yes15 (71%)51 (68%)14 (56%)51(74)    P-value0.76570.0984Tamoxifen only    No12 (50%)37 (51%)13 (45%)34 (54%)    Yes12 (50%)35 (49%)16 (55%)29 (46%)    P-value0.90670.4177Fused    No18 (40%)61 (41%)24 (44%)52 (39%)    Yes27 (60%)86 (59%)30 (56%)80 (61%)    P-value0.85870.5259Mammo responseaLetrozole only    No13 (62%)47 (63%)17 (68%)42 (61%)    Yes8 (38%)28 (37%)8 (32%)27 (39%)    P-value0.94940.5297Tamoxifen only    No19 (79%)54 (75%)23 (79%)48 (76%)    Yes5 (21%)18 (25%)6 (21%)15 (24%)    P-value0.68030.7418Fused    No32 (71%)101 (69%)40 (74%)90 (68%)    Yes13 (29%)46 (31%)14 (26%)42 (32%)    P-value0.76040.4278Ultrasound responseaLetrozole only    No12 (67%)39 (56%)16 (73%)34 (52%)    Yes6 (33%)31 (44%)6 (27%)31 (48%)    P-value0.40380.0959Tamoxifen only    No13 (68%)44 (64%)15 (60%)41 (69%)    Yes6 (32%)25 (36%)10 (60%)18 (31%)    P-value0.70850.4016Fused    No25 (68%)83 (60%)31 (66%)75 (60%)    Yes12 (32%)56 (40%)16 (34%)49 (40%)    P-value0.38450.5116Response rate refers to the percentage of patients with a complete or partial responseaResponse definitions by WHO criteria have been previously reported [11]. The X2 test was applied with Fisher's exact test if a count in any cell was less than 5Table 3Paired Ki67 data before and after letrozole/tamoxifen therapy according to aromatase protein expression status in breast cancer cells/stromal cellsKi67 [Geometric mean (95% CI)]aAromatase protein expressionCancer cellsStromal cellsNegativePositiveNegativePositiveLetrozole only    Pre5.54 (2.54-12.08)3.56 (2.47-5.14)3.64 (1.70-7.82)3.92 (2.69-5.72)    Post0.70 (0.33-1.49)0.49 (0.31-0.75)0.88 (0.38-2.04)0.44 (0.29-0.68)    P-valueb0.00370.00010.00830.0001Tamoxifen only    Pre5.97 (3.17-11.24)5.63 (4.18-7.58)7.75 (4.46-13.47)4.67 (3.39-6.44)    Post1.72 (0.75-3.97)1.36 (0.88-2.09)1.61 (0.76-3.39)1.23 (0.77-1.95)    P-valueb0.01170.00010.00070.0001a95% CI: confidence IntervalbWilcoxon signed rank test was used to compare paired Ki67 data within each group defined by aromatase expression status
###end p 22
###begin p 23
###xml 144 152 <span type="species:ncbi:9606">patients</span>
Analysis of clinical, mammogram and ultrasound response data according to aromatase protein expression status in tamoxifen or letrozole treated patients
###end p 23
###begin p 24
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Response rate refers to the percentage of patients with a complete or partial response
###end p 24
###begin p 25
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 78 79 78 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
aResponse definitions by WHO criteria have been previously reported [11]. The X2 test was applied with Fisher's exact test if a count in any cell was less than 5
###end p 25
###begin p 26
Paired Ki67 data before and after letrozole/tamoxifen therapy according to aromatase protein expression status in breast cancer cells/stromal cells
###end p 26
###begin p 27
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
a95% CI: confidence Interval
###end p 27
###begin p 28
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bWilcoxon signed rank test was used to compare paired Ki67 data within each group defined by aromatase expression status
###end p 28
###begin title 29
Aromatase expression and relapse-free survival and breast cancer-specific survival
###end title 29
###begin p 30
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 589 590 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 604 605 604 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 656 657 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 659 660 659 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 957 958 957 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 961 963 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1219 1221 1219 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1459 1460 1459 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1518 1519 1518 1519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 1532 1533 1532 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1597 1598 1597 1598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 1601 1608 1601 1608 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;4</label>
###xml 1759 1760 1759 1760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1608 1760 1608 1760 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Univariate and multivariate analysis of pathological tumor size, node status, post-treatment Ki67, post-treatment ER and pre treatment aromatase status<sup>a</sup></p>
###xml 1608 1760 1608 1760 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Univariate and multivariate analysis of pathological tumor size, node status, post-treatment Ki67, post-treatment ER and pre treatment aromatase status<sup>a</sup></p></caption>
###xml 1760 1761 1760 1761 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="7">A</th>
###xml 1760 1761 1760 1761 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="7">A</th></tr>
###xml 1761 1779 1761 1779 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Factor definitions</th>
###xml 1779 1808 1779 1808 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">No. of patients in each group</th>
###xml 1808 1837 1808 1837 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">No. of events/No. of patients</th>
###xml 1837 1858 1837 1858 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Relapse-free survival</th>
###xml 1761 1858 1761 1858 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="3">Factor definitions</th><th align="left" rowspan="3">No. of patients in each group</th><th align="left" rowspan="3">No. of events/No. of patients</th><th align="left" colspan="4">Relapse-free survival</th></tr>
###xml 1858 1878 1858 1878 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Univariable analysis</th>
###xml 1878 1899 1878 1899 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Multivariate analysis</th>
###xml 1858 1899 1858 1899 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="2">Univariable analysis</th><th align="left" colspan="2">Multivariate analysis</th></tr>
###xml 1899 1910 1899 1910 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HR (95% CI)</th>
###xml 1910 1911 1910 1911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1910 1911 1910 1911 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 1911 1922 1911 1922 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HR (95% CI)</th>
###xml 1922 1923 1922 1923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1922 1923 1922 1923 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 1899 1923 1899 1923 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th></tr>
###xml 1760 1923 1760 1923 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" colspan="7">A</th></tr><tr><th align="left" rowspan="3">Factor definitions</th><th align="left" rowspan="3">No. of patients in each group</th><th align="left" rowspan="3">No. of events/No. of patients</th><th align="left" colspan="4">Relapse-free survival</th></tr><tr><th align="left" colspan="2">Univariable analysis</th><th align="left" colspan="2">Multivariate analysis</th></tr><tr><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th></tr></thead>
###xml 1933 1934 1933 1934 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1934 1934 1934 1934 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1923 1949 1923 1949 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tumor size<sup>a</sup><break/>(T1/2 vs. T3/4)</td>
###xml 1949 1955 1949 1955 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">138/33</td>
###xml 1955 1961 1955 1961 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">47/171</td>
###xml 1961 1974 1961 1974 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2.7 (1.4&#8211;5.0)</td>
###xml 1974 1979 1974 1979 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.002</td>
###xml 1979 1995 1979 1995 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2.82 (1.36&#8211;5.85)</td>
###xml 1995 2000 1995 2000 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.006</td>
###xml 1923 2000 1923 2000 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Tumor size<sup>a</sup><break/>(T1/2 vs. T3/4)</td><td char="." align="char">138/33</td><td char="." align="char">47/171</td><td char="(" align="char">2.7 (1.4&#8211;5.0)</td><td char="." align="char">0.002</td><td char="(" align="char">2.82 (1.36&#8211;5.85)</td><td char="." align="char">0.006</td></tr>
###xml 2011 2011 2011 2011 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2000 2023 2000 2023 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Node status<break/>(Yes vs. No)</td>
###xml 2023 2028 2023 2028 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">90/69</td>
###xml 2028 2034 2028 2034 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">44/159</td>
###xml 2034 2047 2034 2047 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">3.9 (1.8&#8211;8.4)</td>
###xml 2047 2053 2047 2053 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0005</td>
###xml 2053 2069 2053 2069 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">3.44 (1.58&#8211;7.48)</td>
###xml 2069 2074 2069 2074 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.002</td>
###xml 2000 2074 2000 2074 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Node status<break/>(Yes vs. No)</td><td char="." align="char">90/69</td><td char="." align="char">44/159</td><td char="(" align="char">3.9 (1.8&#8211;8.4)</td><td char="." align="char">0.0005</td><td char="(" align="char">3.44 (1.58&#8211;7.48)</td><td char="." align="char">0.002</td></tr>
###xml 2107 2108 2107 2108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2074 2108 2074 2108 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ki67 level, per 2.7 fold increase<sup>b</sup></td>
###xml 2108 2108 2108 2108 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 2108 2114 2108 2114 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">48/174</td>
###xml 2114 2127 2114 2127 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1.4 (1.2&#8211;1.6)</td>
###xml 2127 2133 2127 2133 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0002</td>
###xml 2133 2148 2133 2148 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1.1 (1.02&#8211;1.09)</td>
###xml 2148 2153 2148 2153 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.003</td>
###xml 2074 2153 2074 2153 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Ki67 level, per 2.7 fold increase<sup>b</sup></td><td char="." align="char"/><td char="." align="char">48/174</td><td char="(" align="char">1.4 (1.2&#8211;1.6)</td><td char="." align="char">0.0002</td><td char="(" align="char">1.1 (1.02&#8211;1.09)</td><td char="." align="char">0.003</td></tr>
###xml 2162 2163 2162 2163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 2163 2163 2163 2163 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2153 2176 2153 2176 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ER Allred<sup>c</sup><break/>(0.2 vs. 3&#8211;8)</td>
###xml 2176 2182 2176 2182 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16/157</td>
###xml 2182 2188 2182 2188 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">48/173</td>
###xml 2188 2201 2188 2201 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2.4 (1.0&#8211;5.3)</td>
###xml 2201 2205 2201 2205 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.04</td>
###xml 2205 2220 2205 2220 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2.74 (1.1&#8211;6.67)</td>
###xml 2220 2224 2220 2224 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.03</td>
###xml 2153 2224 2153 2224 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">ER Allred<sup>c</sup><break/>(0.2 vs. 3&#8211;8)</td><td char="." align="char">16/157</td><td char="." align="char">48/173</td><td char="(" align="char">2.4 (1.0&#8211;5.3)</td><td char="." align="char">0.04</td><td char="(" align="char">2.74 (1.1&#8211;6.67)</td><td char="." align="char">0.03</td></tr>
###xml 2240 2241 2240 2241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 2241 2241 2241 2241 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2224 2269 2224 2269 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Aromatase status<sup>d</sup><break/>(not present versus present)</td>
###xml 2269 2275 2269 2275 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">37/132</td>
###xml 2275 2281 2275 2281 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">48/169</td>
###xml 2281 2297 2281 2297 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1.88 (1.01&#8211;3.47)</td>
###xml 2297 2301 2297 2301 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.04</td>
###xml 2301 2316 2301 2316 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2.34 (1.2&#8211;4.58)</td>
###xml 2316 2320 2316 2320 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.01</td>
###xml 2224 2320 2224 2320 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Aromatase status<sup>d</sup><break/>(not present versus present)</td><td char="." align="char">37/132</td><td char="." align="char">48/169</td><td char="(" align="char">1.88 (1.01&#8211;3.47)</td><td char="." align="char">0.04</td><td char="(" align="char">2.34 (1.2&#8211;4.58)</td><td char="." align="char">0.01</td></tr>
###xml 1923 2320 1923 2320 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Tumor size<sup>a</sup><break/>(T1/2 vs. T3/4)</td><td char="." align="char">138/33</td><td char="." align="char">47/171</td><td char="(" align="char">2.7 (1.4&#8211;5.0)</td><td char="." align="char">0.002</td><td char="(" align="char">2.82 (1.36&#8211;5.85)</td><td char="." align="char">0.006</td></tr><tr><td align="left">Node status<break/>(Yes vs. No)</td><td char="." align="char">90/69</td><td char="." align="char">44/159</td><td char="(" align="char">3.9 (1.8&#8211;8.4)</td><td char="." align="char">0.0005</td><td char="(" align="char">3.44 (1.58&#8211;7.48)</td><td char="." align="char">0.002</td></tr><tr><td align="left">Ki67 level, per 2.7 fold increase<sup>b</sup></td><td char="." align="char"/><td char="." align="char">48/174</td><td char="(" align="char">1.4 (1.2&#8211;1.6)</td><td char="." align="char">0.0002</td><td char="(" align="char">1.1 (1.02&#8211;1.09)</td><td char="." align="char">0.003</td></tr><tr><td align="left">ER Allred<sup>c</sup><break/>(0.2 vs. 3&#8211;8)</td><td char="." align="char">16/157</td><td char="." align="char">48/173</td><td char="(" align="char">2.4 (1.0&#8211;5.3)</td><td char="." align="char">0.04</td><td char="(" align="char">2.74 (1.1&#8211;6.67)</td><td char="." align="char">0.03</td></tr><tr><td align="left">Aromatase status<sup>d</sup><break/>(not present versus present)</td><td char="." align="char">37/132</td><td char="." align="char">48/169</td><td char="(" align="char">1.88 (1.01&#8211;3.47)</td><td char="." align="char">0.04</td><td char="(" align="char">2.34 (1.2&#8211;4.58)</td><td char="." align="char">0.01</td></tr></tbody>
###xml 1760 2320 1760 2320 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7">A</th></tr><tr><th align="left" rowspan="3">Factor definitions</th><th align="left" rowspan="3">No. of patients in each group</th><th align="left" rowspan="3">No. of events/No. of patients</th><th align="left" colspan="4">Relapse-free survival</th></tr><tr><th align="left" colspan="2">Univariable analysis</th><th align="left" colspan="2">Multivariate analysis</th></tr><tr><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Tumor size<sup>a</sup><break/>(T1/2 vs. T3/4)</td><td char="." align="char">138/33</td><td char="." align="char">47/171</td><td char="(" align="char">2.7 (1.4&#8211;5.0)</td><td char="." align="char">0.002</td><td char="(" align="char">2.82 (1.36&#8211;5.85)</td><td char="." align="char">0.006</td></tr><tr><td align="left">Node status<break/>(Yes vs. No)</td><td char="." align="char">90/69</td><td char="." align="char">44/159</td><td char="(" align="char">3.9 (1.8&#8211;8.4)</td><td char="." align="char">0.0005</td><td char="(" align="char">3.44 (1.58&#8211;7.48)</td><td char="." align="char">0.002</td></tr><tr><td align="left">Ki67 level, per 2.7 fold increase<sup>b</sup></td><td char="." align="char"/><td char="." align="char">48/174</td><td char="(" align="char">1.4 (1.2&#8211;1.6)</td><td char="." align="char">0.0002</td><td char="(" align="char">1.1 (1.02&#8211;1.09)</td><td char="." align="char">0.003</td></tr><tr><td align="left">ER Allred<sup>c</sup><break/>(0.2 vs. 3&#8211;8)</td><td char="." align="char">16/157</td><td char="." align="char">48/173</td><td char="(" align="char">2.4 (1.0&#8211;5.3)</td><td char="." align="char">0.04</td><td char="(" align="char">2.74 (1.1&#8211;6.67)</td><td char="." align="char">0.03</td></tr><tr><td align="left">Aromatase status<sup>d</sup><break/>(not present versus present)</td><td char="." align="char">37/132</td><td char="." align="char">48/169</td><td char="(" align="char">1.88 (1.01&#8211;3.47)</td><td char="." align="char">0.04</td><td char="(" align="char">2.34 (1.2&#8211;4.58)</td><td char="." align="char">0.01</td></tr></tbody></table>
###xml 2320 2321 2320 2321 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="7">B</th>
###xml 2320 2321 2320 2321 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="7">B</th></tr>
###xml 2321 2339 2321 2339 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Factor definitions</th>
###xml 2339 2368 2339 2368 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">No. of patients in each group</th>
###xml 2368 2397 2368 2397 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">No. of events/No. of patients</th>
###xml 2397 2428 2397 2428 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Breast cancer-specific survival</th>
###xml 2321 2428 2321 2428 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="3">Factor definitions</th><th align="left" rowspan="3">No. of patients in each group</th><th align="left" rowspan="3">No. of events/No. of patients</th><th align="left" colspan="4">Breast cancer-specific survival</th></tr>
###xml 2428 2448 2428 2448 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Univariable analysis</th>
###xml 2448 2469 2448 2469 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Multivariate analysis</th>
###xml 2428 2469 2428 2469 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="2">Univariable analysis</th><th align="left" colspan="2">Multivariate analysis</th></tr>
###xml 2469 2480 2469 2480 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HR (95% CI)</th>
###xml 2480 2481 2480 2481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2480 2481 2480 2481 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 2481 2492 2481 2492 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HR (95% CI)</th>
###xml 2492 2493 2492 2493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2492 2493 2492 2493 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 2469 2493 2469 2493 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th></tr>
###xml 2320 2493 2320 2493 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" colspan="7">B</th></tr><tr><th align="left" rowspan="3">Factor definitions</th><th align="left" rowspan="3">No. of patients in each group</th><th align="left" rowspan="3">No. of events/No. of patients</th><th align="left" colspan="4">Breast cancer-specific survival</th></tr><tr><th align="left" colspan="2">Univariable analysis</th><th align="left" colspan="2">Multivariate analysis</th></tr><tr><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th></tr></thead>
###xml 2503 2503 2503 2503 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2493 2518 2493 2518 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tumor size<break/>(T1/2 vs. T3/4)</td>
###xml 2518 2524 2518 2524 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">138/33</td>
###xml 2524 2530 2524 2530 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24/171</td>
###xml 2530 2543 2530 2543 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">3.5 (1.5&#8211;8.3)</td>
###xml 2543 2548 2543 2548 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.004</td>
###xml 2548 2564 2548 2564 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">3.42 (1.21&#8211;9.66)</td>
###xml 2564 2568 2564 2568 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.02</td>
###xml 2493 2568 2493 2568 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Tumor size<break/>(T1/2 vs. T3/4)</td><td char="." align="char">138/33</td><td char="." align="char">24/171</td><td char="(" align="char">3.5 (1.5&#8211;8.3)</td><td char="." align="char">0.004</td><td char="(" align="char">3.42 (1.21&#8211;9.66)</td><td char="." align="char">0.02</td></tr>
###xml 2579 2579 2579 2579 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2568 2591 2568 2591 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Node status<break/>(Yes vs. No)</td>
###xml 2591 2596 2591 2596 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">90/69</td>
###xml 2596 2602 2596 2602 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">22/159</td>
###xml 2602 2616 2602 2616 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">4.6 (1.4&#8211;15.8)</td>
###xml 2616 2620 2616 2620 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.01</td>
###xml 2620 2637 2620 2637 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">4.05 (1.14&#8211;14.38)</td>
###xml 2637 2641 2637 2641 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.03</td>
###xml 2568 2641 2568 2641 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Node status<break/>(Yes vs. No)</td><td char="." align="char">90/69</td><td char="." align="char">22/159</td><td char="(" align="char">4.6 (1.4&#8211;15.8)</td><td char="." align="char">0.01</td><td char="(" align="char">4.05 (1.14&#8211;14.38)</td><td char="." align="char">0.03</td></tr>
###xml 2641 2674 2641 2674 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ki67 level, per 2.7 fold increase</td>
###xml 2674 2674 2674 2674 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 2674 2680 2674 2680 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25/174</td>
###xml 2680 2693 2680 2693 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1.4 (1.1&#8211;1.7)</td>
###xml 2693 2698 2693 2698 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.009</td>
###xml 2698 2713 2698 2713 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1.05 (1.0&#8211;1.11)</td>
###xml 2713 2717 2713 2717 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.06</td>
###xml 2641 2717 2641 2717 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Ki67 level, per 2.7 fold increase</td><td char="." align="char"/><td char="." align="char">25/174</td><td char="(" align="char">1.4 (1.1&#8211;1.7)</td><td char="." align="char">0.009</td><td char="(" align="char">1.05 (1.0&#8211;1.11)</td><td char="." align="char">0.06</td></tr>
###xml 2726 2726 2726 2726 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2717 2739 2717 2739 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ER Allred<break/>(0.2 vs. 3&#8211;8)</td>
###xml 2739 2745 2739 2745 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16/157</td>
###xml 2745 2751 2745 2751 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25/173</td>
###xml 2751 2765 2751 2765 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">4.3 (1.6&#8211;11.7)</td>
###xml 2765 2770 2765 2770 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.005</td>
###xml 2770 2786 2770 2786 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">7.98 (2.58&#8211;24.7)</td>
###xml 2786 2792 2786 2792 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0003</td>
###xml 2717 2792 2717 2792 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">ER Allred<break/>(0.2 vs. 3&#8211;8)</td><td char="." align="char">16/157</td><td char="." align="char">25/173</td><td char="(" align="char">4.3 (1.6&#8211;11.7)</td><td char="." align="char">0.005</td><td char="(" align="char">7.98 (2.58&#8211;24.7)</td><td char="." align="char">0.0003</td></tr>
###xml 2808 2808 2808 2808 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2792 2836 2792 2836 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Aromatase status<break/>(not present versus present)</td>
###xml 2836 2842 2836 2842 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">37/132</td>
###xml 2842 2848 2842 2848 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24/169</td>
###xml 2848 2863 2848 2863 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2.82 (1.2&#8211;6.63)</td>
###xml 2863 2867 2863 2867 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.02</td>
###xml 2867 2883 2867 2883 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">3.76 (1.42&#8211;9.98)</td>
###xml 2883 2888 2883 2888 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.008</td>
###xml 2792 2888 2792 2888 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Aromatase status<break/>(not present versus present)</td><td char="." align="char">37/132</td><td char="." align="char">24/169</td><td char="(" align="char">2.82 (1.2&#8211;6.63)</td><td char="." align="char">0.02</td><td char="(" align="char">3.76 (1.42&#8211;9.98)</td><td char="." align="char">0.008</td></tr>
###xml 2493 2888 2493 2888 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Tumor size<break/>(T1/2 vs. T3/4)</td><td char="." align="char">138/33</td><td char="." align="char">24/171</td><td char="(" align="char">3.5 (1.5&#8211;8.3)</td><td char="." align="char">0.004</td><td char="(" align="char">3.42 (1.21&#8211;9.66)</td><td char="." align="char">0.02</td></tr><tr><td align="left">Node status<break/>(Yes vs. No)</td><td char="." align="char">90/69</td><td char="." align="char">22/159</td><td char="(" align="char">4.6 (1.4&#8211;15.8)</td><td char="." align="char">0.01</td><td char="(" align="char">4.05 (1.14&#8211;14.38)</td><td char="." align="char">0.03</td></tr><tr><td align="left">Ki67 level, per 2.7 fold increase</td><td char="." align="char"/><td char="." align="char">25/174</td><td char="(" align="char">1.4 (1.1&#8211;1.7)</td><td char="." align="char">0.009</td><td char="(" align="char">1.05 (1.0&#8211;1.11)</td><td char="." align="char">0.06</td></tr><tr><td align="left">ER Allred<break/>(0.2 vs. 3&#8211;8)</td><td char="." align="char">16/157</td><td char="." align="char">25/173</td><td char="(" align="char">4.3 (1.6&#8211;11.7)</td><td char="." align="char">0.005</td><td char="(" align="char">7.98 (2.58&#8211;24.7)</td><td char="." align="char">0.0003</td></tr><tr><td align="left">Aromatase status<break/>(not present versus present)</td><td char="." align="char">37/132</td><td char="." align="char">24/169</td><td char="(" align="char">2.82 (1.2&#8211;6.63)</td><td char="." align="char">0.02</td><td char="(" align="char">3.76 (1.42&#8211;9.98)</td><td char="." align="char">0.008</td></tr></tbody>
###xml 2320 2888 2320 2888 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7">B</th></tr><tr><th align="left" rowspan="3">Factor definitions</th><th align="left" rowspan="3">No. of patients in each group</th><th align="left" rowspan="3">No. of events/No. of patients</th><th align="left" colspan="4">Breast cancer-specific survival</th></tr><tr><th align="left" colspan="2">Univariable analysis</th><th align="left" colspan="2">Multivariate analysis</th></tr><tr><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Tumor size<break/>(T1/2 vs. T3/4)</td><td char="." align="char">138/33</td><td char="." align="char">24/171</td><td char="(" align="char">3.5 (1.5&#8211;8.3)</td><td char="." align="char">0.004</td><td char="(" align="char">3.42 (1.21&#8211;9.66)</td><td char="." align="char">0.02</td></tr><tr><td align="left">Node status<break/>(Yes vs. No)</td><td char="." align="char">90/69</td><td char="." align="char">22/159</td><td char="(" align="char">4.6 (1.4&#8211;15.8)</td><td char="." align="char">0.01</td><td char="(" align="char">4.05 (1.14&#8211;14.38)</td><td char="." align="char">0.03</td></tr><tr><td align="left">Ki67 level, per 2.7 fold increase</td><td char="." align="char"/><td char="." align="char">25/174</td><td char="(" align="char">1.4 (1.1&#8211;1.7)</td><td char="." align="char">0.009</td><td char="(" align="char">1.05 (1.0&#8211;1.11)</td><td char="." align="char">0.06</td></tr><tr><td align="left">ER Allred<break/>(0.2 vs. 3&#8211;8)</td><td char="." align="char">16/157</td><td char="." align="char">25/173</td><td char="(" align="char">4.3 (1.6&#8211;11.7)</td><td char="." align="char">0.005</td><td char="(" align="char">7.98 (2.58&#8211;24.7)</td><td char="." align="char">0.0003</td></tr><tr><td align="left">Aromatase status<break/>(not present versus present)</td><td char="." align="char">37/132</td><td char="." align="char">24/169</td><td char="(" align="char">2.82 (1.2&#8211;6.63)</td><td char="." align="char">0.02</td><td char="(" align="char">3.76 (1.42&#8211;9.98)</td><td char="." align="char">0.008</td></tr></tbody></table>
###xml 2888 2889 2888 2889 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 3061 3063 3061 3063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 2888 3064 2888 3064 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32"><sup>a</sup>The four elements of the preoperative endocrine relapse index (PEPI) score (pathological T and N stage, surgical specimen ER and Ki67 status has been previously described [<xref ref-type="bibr" rid="CR14">14</xref>]</p>
###xml 3064 3065 3064 3065 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 3209 3211 3209 3211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 3064 3212 3064 3212 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33"><sup>b</sup>Surgical specimen Ki67 was analyzed as the natural log interval, or per 2.7 fold increase according to the original scale of percentage values [<xref ref-type="bibr" rid="CR14">14</xref>]</p>
###xml 3212 3213 3212 3213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 3212 3409 3212 3409 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34"><sup>c</sup>The ER analysis refers to the post-treatment values, before treatment all the tumors in this data set were ER positive. In the PEPI model, an Allred cut off of 0 or 2 is used to define ER negative</p>
###xml 3409 3410 3409 3410 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 3551 3552 3551 3552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 3409 3606 3409 3606 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35"><sup>d</sup>The aromatase expression status was defined as present or positive if any positive staining presented in invasive breast cancer cells. Table&#160;<xref rid="Tab4" ref-type="table">4</xref>A and B shows the RFS data and BCSS data, respectively</p>
###xml 2888 3606 2888 3606 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32"><sup>a</sup>The four elements of the preoperative endocrine relapse index (PEPI) score (pathological T and N stage, surgical specimen ER and Ki67 status has been previously described [<xref ref-type="bibr" rid="CR14">14</xref>]</p><p textid="33"><sup>b</sup>Surgical specimen Ki67 was analyzed as the natural log interval, or per 2.7 fold increase according to the original scale of percentage values [<xref ref-type="bibr" rid="CR14">14</xref>]</p><p textid="34"><sup>c</sup>The ER analysis refers to the post-treatment values, before treatment all the tumors in this data set were ER positive. In the PEPI model, an Allred cut off of 0 or 2 is used to define ER negative</p><p textid="35"><sup>d</sup>The aromatase expression status was defined as present or positive if any positive staining presented in invasive breast cancer cells. Table&#160;<xref rid="Tab4" ref-type="table">4</xref>A and B shows the RFS data and BCSS data, respectively</p></table-wrap-foot>
###xml 1601 3606 1601 3606 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table&#160;4</label><caption><p textid="31">Univariate and multivariate analysis of pathological tumor size, node status, post-treatment Ki67, post-treatment ER and pre treatment aromatase status<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7">A</th></tr><tr><th align="left" rowspan="3">Factor definitions</th><th align="left" rowspan="3">No. of patients in each group</th><th align="left" rowspan="3">No. of events/No. of patients</th><th align="left" colspan="4">Relapse-free survival</th></tr><tr><th align="left" colspan="2">Univariable analysis</th><th align="left" colspan="2">Multivariate analysis</th></tr><tr><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Tumor size<sup>a</sup><break/>(T1/2 vs. T3/4)</td><td char="." align="char">138/33</td><td char="." align="char">47/171</td><td char="(" align="char">2.7 (1.4&#8211;5.0)</td><td char="." align="char">0.002</td><td char="(" align="char">2.82 (1.36&#8211;5.85)</td><td char="." align="char">0.006</td></tr><tr><td align="left">Node status<break/>(Yes vs. No)</td><td char="." align="char">90/69</td><td char="." align="char">44/159</td><td char="(" align="char">3.9 (1.8&#8211;8.4)</td><td char="." align="char">0.0005</td><td char="(" align="char">3.44 (1.58&#8211;7.48)</td><td char="." align="char">0.002</td></tr><tr><td align="left">Ki67 level, per 2.7 fold increase<sup>b</sup></td><td char="." align="char"/><td char="." align="char">48/174</td><td char="(" align="char">1.4 (1.2&#8211;1.6)</td><td char="." align="char">0.0002</td><td char="(" align="char">1.1 (1.02&#8211;1.09)</td><td char="." align="char">0.003</td></tr><tr><td align="left">ER Allred<sup>c</sup><break/>(0.2 vs. 3&#8211;8)</td><td char="." align="char">16/157</td><td char="." align="char">48/173</td><td char="(" align="char">2.4 (1.0&#8211;5.3)</td><td char="." align="char">0.04</td><td char="(" align="char">2.74 (1.1&#8211;6.67)</td><td char="." align="char">0.03</td></tr><tr><td align="left">Aromatase status<sup>d</sup><break/>(not present versus present)</td><td char="." align="char">37/132</td><td char="." align="char">48/169</td><td char="(" align="char">1.88 (1.01&#8211;3.47)</td><td char="." align="char">0.04</td><td char="(" align="char">2.34 (1.2&#8211;4.58)</td><td char="." align="char">0.01</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7">B</th></tr><tr><th align="left" rowspan="3">Factor definitions</th><th align="left" rowspan="3">No. of patients in each group</th><th align="left" rowspan="3">No. of events/No. of patients</th><th align="left" colspan="4">Breast cancer-specific survival</th></tr><tr><th align="left" colspan="2">Univariable analysis</th><th align="left" colspan="2">Multivariate analysis</th></tr><tr><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Tumor size<break/>(T1/2 vs. T3/4)</td><td char="." align="char">138/33</td><td char="." align="char">24/171</td><td char="(" align="char">3.5 (1.5&#8211;8.3)</td><td char="." align="char">0.004</td><td char="(" align="char">3.42 (1.21&#8211;9.66)</td><td char="." align="char">0.02</td></tr><tr><td align="left">Node status<break/>(Yes vs. No)</td><td char="." align="char">90/69</td><td char="." align="char">22/159</td><td char="(" align="char">4.6 (1.4&#8211;15.8)</td><td char="." align="char">0.01</td><td char="(" align="char">4.05 (1.14&#8211;14.38)</td><td char="." align="char">0.03</td></tr><tr><td align="left">Ki67 level, per 2.7 fold increase</td><td char="." align="char"/><td char="." align="char">25/174</td><td char="(" align="char">1.4 (1.1&#8211;1.7)</td><td char="." align="char">0.009</td><td char="(" align="char">1.05 (1.0&#8211;1.11)</td><td char="." align="char">0.06</td></tr><tr><td align="left">ER Allred<break/>(0.2 vs. 3&#8211;8)</td><td char="." align="char">16/157</td><td char="." align="char">25/173</td><td char="(" align="char">4.3 (1.6&#8211;11.7)</td><td char="." align="char">0.005</td><td char="(" align="char">7.98 (2.58&#8211;24.7)</td><td char="." align="char">0.0003</td></tr><tr><td align="left">Aromatase status<break/>(not present versus present)</td><td char="." align="char">37/132</td><td char="." align="char">24/169</td><td char="(" align="char">2.82 (1.2&#8211;6.63)</td><td char="." align="char">0.02</td><td char="(" align="char">3.76 (1.42&#8211;9.98)</td><td char="." align="char">0.008</td></tr></tbody></table><table-wrap-foot><p textid="32"><sup>a</sup>The four elements of the preoperative endocrine relapse index (PEPI) score (pathological T and N stage, surgical specimen ER and Ki67 status has been previously described [<xref ref-type="bibr" rid="CR14">14</xref>]</p><p textid="33"><sup>b</sup>Surgical specimen Ki67 was analyzed as the natural log interval, or per 2.7 fold increase according to the original scale of percentage values [<xref ref-type="bibr" rid="CR14">14</xref>]</p><p textid="34"><sup>c</sup>The ER analysis refers to the post-treatment values, before treatment all the tumors in this data set were ER positive. In the PEPI model, an Allred cut off of 0 or 2 is used to define ER negative</p><p textid="35"><sup>d</sup>The aromatase expression status was defined as present or positive if any positive staining presented in invasive breast cancer cells. Table&#160;<xref rid="Tab4" ref-type="table">4</xref>A and B shows the RFS data and BCSS data, respectively</p></table-wrap-foot></table-wrap>
###xml 3606 3612 3606 3612 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 3742 3743 3742 3743 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 3907 3908 3907 3908 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 3612 4285 3612 4285 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">Kaplan&#8211;Meier curves for relapse-free and breast cancer-specific survival by aromatase protein expression status in cancer cells. (<bold>a</bold>) Relapse-free survival (RFS) for patients with aromatase protein expression positive (green or upper curve) versus negative (red or lower curve) in cancer cells; (<bold>b</bold>) Breast cancer-specific survival (BCSS) for patients with aromatase protein expression positive (green or upper curve) versus negative (red or lower curve) in cancer cells; Censorship observations are marked with open circles; log rank tests were used to estimate the difference between Kaplan&#8211;Meier curves for RFS and BCSS. 95% confidence intervals are provided on each curve</p>
###xml 3612 4285 3612 4285 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">Kaplan&#8211;Meier curves for relapse-free and breast cancer-specific survival by aromatase protein expression status in cancer cells. (<bold>a</bold>) Relapse-free survival (RFS) for patients with aromatase protein expression positive (green or upper curve) versus negative (red or lower curve) in cancer cells; (<bold>b</bold>) Breast cancer-specific survival (BCSS) for patients with aromatase protein expression positive (green or upper curve) versus negative (red or lower curve) in cancer cells; Censorship observations are marked with open circles; log rank tests were used to estimate the difference between Kaplan&#8211;Meier curves for RFS and BCSS. 95% confidence intervals are provided on each curve</p></caption>
###xml 4285 4285 4285 4285 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10549_2008_161_Fig2_HTML" id="MO2"/>
###xml 3606 4285 3606 4285 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="36">Kaplan&#8211;Meier curves for relapse-free and breast cancer-specific survival by aromatase protein expression status in cancer cells. (<bold>a</bold>) Relapse-free survival (RFS) for patients with aromatase protein expression positive (green or upper curve) versus negative (red or lower curve) in cancer cells; (<bold>b</bold>) Breast cancer-specific survival (BCSS) for patients with aromatase protein expression positive (green or upper curve) versus negative (red or lower curve) in cancer cells; Censorship observations are marked with open circles; log rank tests were used to estimate the difference between Kaplan&#8211;Meier curves for RFS and BCSS. 95% confidence intervals are provided on each curve</p></caption><graphic position="anchor" xlink:href="10549_2008_161_Fig2_HTML" id="MO2"/></fig>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
###xml 1786 1794 <span type="species:ncbi:9606">patients</span>
###xml 2346 2354 <span type="species:ncbi:9606">patients</span>
###xml 3777 3785 <span type="species:ncbi:9606">patients</span>
###xml 3953 3961 <span type="species:ncbi:9606">patients</span>
Although there was no association with neoadjuvant response or Ki67 changes, the baseline interactions between aromatase expression, higher ER levels and lower Ki67 levels suggested the possibility that aromatase expression could be a favorable prognostic biomarker for patients undergoing adjuvant endocrine therapy. We therefore examined the impact of aromatase expression on RFS and BCSS (Fig. 2). Tumor aromatase expression was confirmed to have a modest association with a more favorable disease course, with fewer relapse events over time and a significant univariable log rank test P = 0.04 (Fig. 2a) and more prolonged breast cancer survival (Fig. 2b P = 0.01). To determine the independence of baseline aromatase expression as a prognostic marker in our established multivariable models based on the post-treatment surgical sample, the baseline aromatase status was analyzed in the context of the preoperative endocrine relapse index (PEPI) (Table 4) [14]. In the PEPI model pathologic tumor size (T1/2 vs. T3/4), pathological nodal status (negative vs. positive), Ki67 per natural log interval and ER status post therapy (Allred 0-2 vs. Allred 3-8) have been found to be independent factors for RFS and BCSS [14]. When tumor aromatase status was entered into a multivariable Cox model containing these four factors, the presence of aromatase expression in the baseline specimen behaved as an independent favorable prognostic biomarker for both RFS (P = 0.01, HR 2.3 95% 1.2-4.6 for absent expression) (Table 4A) and BCSS (P = 0.008, HR 3.76 95% CI 1.4-10.0 for absent expression) (Table 4B).Table 4Univariate and multivariate analysis of pathological tumor size, node status, post-treatment Ki67, post-treatment ER and pre treatment aromatase statusaAFactor definitionsNo. of patients in each groupNo. of events/No. of patientsRelapse-free survivalUnivariable analysisMultivariate analysisHR (95% CI)PHR (95% CI)PTumor sizea(T1/2 vs. T3/4)138/3347/1712.7 (1.4-5.0)0.0022.82 (1.36-5.85)0.006Node status(Yes vs. No)90/6944/1593.9 (1.8-8.4)0.00053.44 (1.58-7.48)0.002Ki67 level, per 2.7 fold increaseb48/1741.4 (1.2-1.6)0.00021.1 (1.02-1.09)0.003ER Allredc(0.2 vs. 3-8)16/15748/1732.4 (1.0-5.3)0.042.74 (1.1-6.67)0.03Aromatase statusd(not present versus present)37/13248/1691.88 (1.01-3.47)0.042.34 (1.2-4.58)0.01BFactor definitionsNo. of patients in each groupNo. of events/No. of patientsBreast cancer-specific survivalUnivariable analysisMultivariate analysisHR (95% CI)PHR (95% CI)PTumor size(T1/2 vs. T3/4)138/3324/1713.5 (1.5-8.3)0.0043.42 (1.21-9.66)0.02Node status(Yes vs. No)90/6922/1594.6 (1.4-15.8)0.014.05 (1.14-14.38)0.03Ki67 level, per 2.7 fold increase25/1741.4 (1.1-1.7)0.0091.05 (1.0-1.11)0.06ER Allred(0.2 vs. 3-8)16/15725/1734.3 (1.6-11.7)0.0057.98 (2.58-24.7)0.0003Aromatase status(not present versus present)37/13224/1692.82 (1.2-6.63)0.023.76 (1.42-9.98)0.008aThe four elements of the preoperative endocrine relapse index (PEPI) score (pathological T and N stage, surgical specimen ER and Ki67 status has been previously described [14]bSurgical specimen Ki67 was analyzed as the natural log interval, or per 2.7 fold increase according to the original scale of percentage values [14]cThe ER analysis refers to the post-treatment values, before treatment all the tumors in this data set were ER positive. In the PEPI model, an Allred cut off of 0 or 2 is used to define ER negativedThe aromatase expression status was defined as present or positive if any positive staining presented in invasive breast cancer cells. Table 4A and B shows the RFS data and BCSS data, respectivelyFig. 2Kaplan-Meier curves for relapse-free and breast cancer-specific survival by aromatase protein expression status in cancer cells. (a) Relapse-free survival (RFS) for patients with aromatase protein expression positive (green or upper curve) versus negative (red or lower curve) in cancer cells; (b) Breast cancer-specific survival (BCSS) for patients with aromatase protein expression positive (green or upper curve) versus negative (red or lower curve) in cancer cells; Censorship observations are marked with open circles; log rank tests were used to estimate the difference between Kaplan-Meier curves for RFS and BCSS. 95% confidence intervals are provided on each curve
###end p 30
###begin p 31
###xml 151 152 151 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
Univariate and multivariate analysis of pathological tumor size, node status, post-treatment Ki67, post-treatment ER and pre treatment aromatase statusa
###end p 31
###begin p 32
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
aThe four elements of the preoperative endocrine relapse index (PEPI) score (pathological T and N stage, surgical specimen ER and Ki67 status has been previously described [14]
###end p 32
###begin p 33
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
bSurgical specimen Ki67 was analyzed as the natural log interval, or per 2.7 fold increase according to the original scale of percentage values [14]
###end p 33
###begin p 34
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
cThe ER analysis refers to the post-treatment values, before treatment all the tumors in this data set were ER positive. In the PEPI model, an Allred cut off of 0 or 2 is used to define ER negative
###end p 34
###begin p 35
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
dThe aromatase expression status was defined as present or positive if any positive staining presented in invasive breast cancer cells. Table 4A and B shows the RFS data and BCSS data, respectively
###end p 35
###begin p 36
###xml 130 131 130 131 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 295 296 295 296 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
###xml 341 349 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier curves for relapse-free and breast cancer-specific survival by aromatase protein expression status in cancer cells. (a) Relapse-free survival (RFS) for patients with aromatase protein expression positive (green or upper curve) versus negative (red or lower curve) in cancer cells; (b) Breast cancer-specific survival (BCSS) for patients with aromatase protein expression positive (green or upper curve) versus negative (red or lower curve) in cancer cells; Censorship observations are marked with open circles; log rank tests were used to estimate the difference between Kaplan-Meier curves for RFS and BCSS. 95% confidence intervals are provided on each curve
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 606 607 606 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 814 822 <span type="species:ncbi:9606">patients</span>
The clinical significance of intra-tumoral estrogen production has been debated ever since the phenomenon was first documented by Miller et al., in 1974 [15] through the detection of the conversion of radio-labeled androgen to estradiol within breast cancers in vitro. This potential exists in about 60-70% of breast cancers [1-3]. Subsequently infusion studies with radioactive androgens showed that estrogen biosynthesis occurred in situ within the breast [16, 17] and the presence of mRNA for aromatase, the key enzyme in estrogen production, was also demonstrated in breast cancers and adipose tissue [8]. Because aromatase is the last step in the biosynthetic pathway for estradiol, the enzyme has become a critical target for pharmacological inhibitors that achieve endocrine deprivation for post-menopausal patients requiring endocrine treatment for ER+ breast cancer. Consequently third-generation aromatase inhibitors have evolved as the new standard of care for breast cancer treatment for all stages of the disease. It was therefore logical to address the possibility that the presence of aromatase within breast cancers is associated with a particular requirement for estrogen for growth and therefore whether aromatase expressing tumors are more likely to respond to endocrine therapy in general, and to aromatase inhibitors in particular.
###end p 38
###begin p 39
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
The number of studies examining these relationships is few, have utilized small numbers of tumors and come to limited (often conflicting) conclusions [4, 18, 19]. The major reason for this is that the low abundance of aromatase in the breast requires sophisticated, time-consuming and labor intensive methodology and relatively large amounts of fresh tissue. This has precluded routine use in large clinical trials. However the availability of an antibody which can specifically detect aromatase in fixed archival breast cancers has changed this. We can now report results on the presence (and semi-quantitative levels) of aromatase in tumor material obtained from a randomized trial of neoadjuvant endocrine therapy (P024).
###end p 39
###begin p 40
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 289 297 <span type="species:ncbi:9606">patients</span>
Before discussing the findings it is worth considering methodological issues and potential limitations of the study. Firstly, IHC estimation of protein provides no information on activity and protein may be present that is deactivated or inhibited [20]. This certainly will be the case in patients treated with aromatase inhibitors. For this reason we have excluded outcome correlations with aromatase status in "on treatment" samples because we have not validated relationships between aromatase activity and expression in the presence of an endocrine agent. Secondly, because aromatase is present in different compartments of the breast (and at different levels) complete assessment requires quantification of multiple tissue types and an estimate of the relative amounts of each compartment. In this study, to simplify these confounders, we have not used assessments in adipose and benign tissue of tissue sections which were generally low in staining score and proportion. Aromatase scores were highest in the malignant and stromal compartments of breast cancers. However, these were highly related in breast cancers suggesting a field effect of trophic factors regulating aromatase. We have therefore restricted our correlations to the status of the cancer cells which were reliably present in all the samples eligible for analysis and therefore more consistent to score.
###end p 40
###begin p 41
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 651 652 651 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 132 140 <span type="species:ncbi:9606">patients</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
In terms of demographics we have combined the two arms of the P024 trial for long term outcome analysis, not discriminating between patients subsequently treated with tamoxifen or letrozole since all patients received tamoxifen as adjuvant therapy. This has formed a database which represents the largest published series of breast cancers assessed by aromatase IHC. The results show that tumor aromatase was positively and significantly related to smaller tumor size and ER level/status. These findings would be consistent with data published by members of the group on aromatase activity [4] but not with others using IHC with a different antibody [7]. A significant inverse correlation was observed with the proliferation marker, Ki67. To the best of our knowledge there have been no other published studies relating tumor aromatase to proliferation.
###end p 41
###begin p 42
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
In terms of endocrine responsiveness, no significant association was detected between tumor aromatase and clinical response to either letrozole or tamoxifen. While positive correlations have been reported between the presence of in vitro and in vivo aromatase activity and response to aromatase inhibitors, these relationships were not strong and were observed in advanced disease, not in the neoadjuvant setting [18, 19] Other studies on response to tamoxifen have been negative. Thus, the response to endocrine therapy does not appear to be strongly modulated by whether the source of estrogen is autocrine or endocrine.
###end p 42
###begin p 43
###xml 1471 1473 1471 1473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1241 1249 <span type="species:ncbi:9606">patients</span>
Despite a failure to observe significant relationships between aromatase expression and clinical or biomarker response to treatment in the neoadjuvant phase of the study, significant associations were found between the presence of tumor aromatase expression and long-term outcome following neoadjuvant treatment. Thus, tumors with positive aromatase scores had significantly greater RFS and BCSS. It is not possible to ascertain whether this is directly caused by increased sensitivity to endocrine therapy in the adjuvant setting. However, the lack of association of response in the neoadjuvant situation would not be compatible with this. Furthermore the positive correlations with small clinical size and ER status levels (favorable prognostic biomarkers) and the inverse correlation with Ki67 (a poor prognosis biomarker) suggest that aromatase positive tumors may be inherently less aggressive. This is supported by data from multivariable analyses in which tumor aromatase scores predicted for long-term outcome independently of other factors that have been shown to be predictive for outcome in the post neoadjuvant endocrine therapy setting. This finding also implies that the most accurate models for the prediction of outcomes for patients with ER+ disease may combine baseline prognostic biomarker analysis, in combination with the "on-treatment" predictive biomarker analysis derived from an analysis of the tumor after several months of endocrine treatment [14].
###end p 43
###begin p 44
It is therefore suggested that routine IHC measurements of aromatase in breast cancer will not generally aid prediction of neoadjuvant response to endocrine therapy, but may help identify ER positive tumors with favorable long-term outcomes.
###end p 44
###begin title 45
References
###end title 45
###begin article-title 46
The role of aromatase in breast tumors
###end article-title 46
###begin article-title 47
Aromatase inhibitors and breast cancer
###end article-title 47
###begin article-title 48
###xml 38 43 <span type="species:ncbi:9606">human</span>
Significance of aromatase activity in human breast cancer
###end article-title 48
###begin article-title 49
Relationship between tumour aromatase activity, tumour characteristics and response to therapy
###end article-title 49
###begin article-title 50
Aromatase activity in breast tissue
###end article-title 50
###begin article-title 51
Prognostic value of breast cancer aromatase
###end article-title 51
###begin article-title 52
Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation
###end article-title 52
###begin article-title 53
###xml 43 48 <span type="species:ncbi:9606">human</span>
Controversies of aromatase localization in human breast cancer-stromal versus parenchymal cells
###end article-title 53
###begin article-title 54
The validation of new aromatase monoclonal antibodies for immunohistochemistry-a correlation with biochemical activities in 46 cases of breast cancer
###end article-title 54
###begin article-title 55
###xml 26 31 <span type="species:ncbi:9606">human</span>
Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells
###end article-title 55
###begin article-title 56
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study
###end article-title 56
###begin article-title 57
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial
###end article-title 57
###begin article-title 58
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status
###end article-title 58
###begin article-title 59
###xml 26 31 <span type="species:ncbi:9606">human</span>
Oestradiol synthesis by a human breast carcinoma
###end article-title 59
###begin article-title 60
Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues
###end article-title 60
###begin article-title 61
Uptake and synthesis of steroid hormones by the breast
###end article-title 61
###begin article-title 62
###xml 36 41 <span type="species:ncbi:9606">human</span>
Aromatisation of androstenedione by human breast cancer tissue: correlation with hormone receptor activity and possible biologic significance
###end article-title 62
###begin article-title 63
An integrated view of aromatase and its inhibition
###end article-title 63
###begin article-title 64
Endocrine and clinical endpoints of exemestane as neoadjuvant therapy
###end article-title 64

